Page last updated: 2024-11-08

monensin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Monensin: An antiprotozoal agent produced by Streptomyces cinnamonensis. It exerts its effect during the development of first-generation trophozoites into first-generation schizonts within the intestinal epithelial cells. It does not interfere with hosts' development of acquired immunity to the majority of coccidial species. Monensin is a sodium and proton selective ionophore and is widely used as such in biochemical studies. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

monensin A : A spiroketal, monensin A is the major component of monensin, a mixture of antibiotic substances produced by Streptomyces cinnamonensis. An antiprotozoal, it is used as the sodium salt as a feed additive for the prevention of coccidiosis in poultry and as a growth promoter in cattle. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID441145
CHEMBL ID256105
CHEBI ID27617
SCHEMBL ID55367
MeSH IDM0014007
PubMed CID23667299
CHEMBL ID1908308
SCHEMBL ID4057708
MeSH IDM0014007

Synonyms (104)

Synonym
lilly 673140
rumensin (as sodium salt)
stereoisomer of 2-(2-ethyloctahydro-3'-methyl-5'-(tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2h-pyran-2-yl)(2,2'-bifuran-5-yl))-9-hydroxy-beta-methoxy-alpha,gamma,2,8-tetramethyl-1,6-dioxaspiro(4.5)decan-7-butanoic acid
monensinum [inn-latin]
hsdb 7031
monensina [inn-spanish]
einecs 241-154-0
1,6-dioxaspiro(4.5)decane-7-butyric acid, 2-(5-ethyltetrahydro-5-(tetrahydro-3-methyl-5-(tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2h-pyran-2-yl)-2-furyl)-2-furyl)-9-hydroxy-beta-methoxy-alpha,gamma,2,8-tetramethyl-
monelan
atcc 15413
monensic acid
coban (as sodium salt)
BPBIO1_000810
BSPBIO_000736
PRESTWICK3_000748
(2s,3r,4s)-4-[(3s,5r,7s,8r,9s)-3-[(2r,5s)-5-ethyl-5-[(2r,3s,5r)-5-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-tetrahydropyran-2-yl]-3-methyl-tetrahydrofuran-2-yl]tetrahydrofuran-2-yl]-7-hydroxy-3,8-dimethyl-4,10-dioxaspiro[4.5]decan-9-yl]-3-me
monensine
a 3823a
2-[5-ethyltetrahydro-5-[tetrahydro-3-methyl-5-[tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2h-pyran-2-yl]-2-furyl]-2-furyl]-9-hydroxy-.beta.-methoxy-.alpha.,.gamma.,2,8-tetramethyl-1,6-dioxaspiro[4.5]decane-7-butyric acid
C06693
monensin
monensin a
CHEMBL256105
e714
a-3823a
chebi:27617 ,
D08228
elancoban [veterinary] (tn)
monensin (inn)
rumensin 90
906o0yj6zp ,
unii-906o0yj6zp
monensin [usan:usp:inn:ban]
monensina
monensinum
AKOS015964837
(2s,3r,4s)-4-[(2s,5r,7s,8r,9s)-2-{(2s,2'r,3's,5r,5'r)-2-ethyl-5'-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyltetrahydro-2h-pyran-2-yl]-3'-methyloctahydro-2,2'-bifuran-5-yl}-9-hydroxy-2,8-dimethyl-1,6-dioxaspiro[4.5]dec-7-yl]-3-methoxy-2-methylp
monensin [green book]
monensin [hsdb]
2-(2-ethyloctahydro-3'-methyl-5'-(tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2h-pyran-2-yl)(2,2'-bifuran-5-yl))-9-hydroxy-.beta.-methoxy-.alpha.,.gamma.,2,8-tetramethyl-1,6-dioxaspiro(4.5)decan-7-butanoic acid
2-(5-ethyltetrahydro-5-(tetrahydro-3-methyl-5-(tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2h-pyran-2-yl)-2-furyl)-2-furyl)-9-hydroxy-.beta.-methoxy-.alpha.,.gamma.,2,8-tetramethyl-1,6-dioxaspiro(4.5)decane-7-butyric acid
monensin [usp impurity]
monensin [inn]
monensin [mart.]
4-(2-(2-ethyl-3'-methyl-5'-(tetrahydro-6-hydroxy-6-hydroxymethyl-3,5-dimethylpyran-2-yl)perhydro-2,2'-bifuran-5-yl)-9-hydroxy-2,8-dimethyl-1,6-dioxaspiro(4.5)dec-7-yl)3-methoxy-2-methylpentanoic acid
monensin [mi]
monensin [usan]
monensin [usp monograph]
BRD-K55375480-236-03-0
SCHEMBL55367
DTXSID4048561 ,
SR-05000013702-2
J-010665
Q3493048
DB11430
monensinsodiumsalt
CS-0032703
HY-N4302
coban 90
(2s,3r,4s)-4-((2s,5r,7s,8r,9s)-2-((2s,2'r,3's,5r,5'r)-2-ethyl-5'-((2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyltetrahydro-2h-pyran-2-yl)-3'-methyloctahydro-2,2'-bifuran-5-yl)-9-hydroxy-2,8-dimethyl-1,6-dioxaspiro(4.5)dec-7-yl)-3-methoxy-2-methylp
2-(5-ethyltetrahydro-5-(tetrahydro-3-methyl-5-(tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2h-pyran-2-yl)-2-furyl)-2-furyl)-9-hydroxy-beta-methoxy-alpha,gamma,2,8-tetramethyl-1,6-dioxaspiro(4.5)decane-7-butyric acid
monovet 90
monensin (usan:usp:inn:ban)
pasture gainer block 20 r350, pasture gainer block 20 r350 no se, pasture gainer block 37 r350, pasture gainer block 37 r350 no se
cycleguard and monovet
2-(2-ethyloctahydro-3'-methyl-5'-(tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2h-pyran-2-yl)(2,2'-bifuran-5-yl))-9-hydroxy-beta-methoxy-alpha,gamma,2,8-tetramethyl-1,6-dioxaspiro(4.5)decan-7-butanoic acid
elancoban (veterinary)
monensina (inn-spanish)
dtxcid7028190
monensin granulated
monensinum (inn-latin)
monensin (usp monograph)
monensin (mart.)
monensinum (latin)
monensin (usp impurity)
smr001233320
MLS002153986
cas-22373-78-0
NCGC00017089-01
HMS2097E18
tox21_113191
dtxsid2045573 ,
tox21_110771
CHEMBL1908308
monensin a sodium salt
AM84797
S2324
CCG-220748
SCHEMBL4057708
XOIQMTLWECTKJL-FBZUZRIGSA-M
AKOS025147337
2-[5-ethyltetrahydro-5-[tetrahydro-3-methyl-5-[tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2h-pyran-2-yl]-2-furyl]-2-furyl]-9-hydroxy-?-methoxy-?,?,2,8-tetramethyl-1,6-dioxaspiro[4.5]decane-7-butyric acid sodium salt
c36h61nao11
HMS3714E18
M2573
sodium;(2s,3r,4s)-4-[(2s,5r,7s,8r,9s)-2-[(2r,5s)-5-ethyl-5-[(2r,3s,5r)-5-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]oxolan-2-yl]-7-hydroxy-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-3-methoxy-2-methylpentanoate
monensin sodium 100 microg/ml in acetonitrile
CS-0007881
HY-N0150
HB4882
4-[2-[5-ethyl-5-[5-[6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]- 3-methyloxolan-2-yl]oxolan-2-yl]- 9-hydroxy-2,8-dimethyl-1,6-dioxaspiro[4.5]dec-7-yl]-3-methoxy-2-methylpentanoic acid sodium salt
E78700
AS-0826
sodium (2s,3r,4s)-4-[(2s,5r,7s,8r,9s)-2-[(2s,2'r,3's,5r,5'r)-2-ethyl-5'-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3'-methyl-[2,2'-bioxolan]-5-yl]-9-hydroxy-2,8-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl]-3-methoxy-2-methylpentanoate

Research Excerpts

Overview

Monensin is an ionophore for monovalent cations, which is frequently used to prevent ketosis and to enhance performance in dairy cows. Monensin A is a prototypical natural polyether polyketide antibiotic.

ExcerptReferenceRelevance
"Monensin is an ionophore for monovalent cations, which is frequently used to prevent ketosis and to enhance performance in dairy cows. "( Na
Boldt, C; Pfirrmann, J; Schleicher, L; Seifert, J; Steuber, J; Trautmann, A, 2021
)
2.06
"Monensin is a carboxyl polyether ionophore that potently inhibits the growth of various cancer types."( Monensin Inhibits Anaplastic Thyroid Cancer via Disrupting Mitochondrial Respiration and AMPK/mTOR Signaling.
Chen, S; Jing, H; Li, Y; Sun, Q; Yu, X, 2022
)
2.89
"Monensin is an ionophore antibiotic that inhibits the growth of cancer cells. "( Investigation of the anticancer mechanism of monensin via apoptosis-related factors in SH-SY5Y neuroblastoma cells.
Oy, C; Secme, M; Serter Kocoglu, S; Sunay, FB, 2023
)
2.61
"Monensin A is a prototypical natural polyether polyketide antibiotic. "( Triepoxide formation by a flavin-dependent monooxygenase in monensin biosynthesis.
Chen, X; Deng, Y; Guan, Y; Kim, CY; Liu, N; Mathews, II; Nitka, TA; Vukovic, L; Wang, Q; Xiao, H; Yadav, A; Yang, H, 2023
)
2.6
"Monensin (MON) is a coccidiostat used as a growth promoter that can reach the environment through fertilization with manure from farm animals. "( Effect of the veterinary ionophore monensin on the structure and activity of a tropical soil bacterial community.
Arias-Andrés, MJ; Fernández Montes de Oca, ML; Granados-Chinchilla, F; Rodríguez, C, 2020
)
2.28
"Monensin is a carrier antibiotic that has been reported to inhibit the growth of cancer cells; however, its impacts on breast cancer cells have not been reported."( Monensin inhibits proliferation, migration, and promotes apoptosis of breast cancer cells via downregulating UBA2.
Gu, J; Huang, L; Zhang, Y, 2020
)
2.72
"Monensin is an ionophore antibiotic used as a feed additive and growth promoter in cattle production worldwide. "( Monensin occurrence in surface water and its impact on aquatic biota in a stream of the southeast Pampas, Argentina.
Aparicio, VC; Cantón, G; Costa, JL; De Gerónimo, E; Iturburu, FG; Menone, ML; Okada, E; Pérez, DJ, 2021
)
3.51
"Monensin is a commonly used veterinary antibiotic with a narrow safety range. "( Rhabdomyolysis and hepatotoxicity following accidental monensin ingestion: A report of two cases.
Cui, S; Zhang, J; Zhang, Z, 2021
)
2.31
"Monensin is a common antiparasitic drug given to poultry that contaminates poultry manure and bedding material (broiler litter). "( Long-term broiler litter amendments can alter the soil's capacity to sorb monensin.
Cabrera, M; Doydora, SA; Huang, CH; Mantripragada, N; Pavlostathis, SG; Rema, J; Sun, P; Thompson, A, 2017
)
2.13
"Monensin is a veterinary antibiotic with a narrow therapeutic window that has led to lethal intoxication in many animal species. "( Survival After Severe Rhabdomyolysis Following Monensin Ingestion.
Blain, M; Chen, B; Garrard, A; Halliday Gittinger, M; Poppenga, R; Valento, M, 2017
)
2.15
"Monensin is a veterinary medication not approved for human use by the US Food and Drug Administration. "( Survival After Severe Rhabdomyolysis Following Monensin Ingestion.
Blain, M; Chen, B; Garrard, A; Halliday Gittinger, M; Poppenga, R; Valento, M, 2017
)
2.15
"Monensin (Mon) is an anticoccidial polyether ionophore widely used to control coccidiosis. "( Resistance towards monensin is proposed to be acquired in a Toxoplasma gondii model by reduced invasion and egress activities, in addition to increased intracellular replication.
Bangoura, B; Baumann, S; Daugschies, A; Honscha, W; Schmidt, J; Thabet, A; VON Bergen, M, 2018
)
2.25
"Monensin A (MON) is a polyether ionophore antibiotic, which shows a wide spectrum of biological activity. "( One-pot synthesis and antiproliferative activity of novel double-modified derivatives of the polyether ionophore monensin A.
Huczyński, A; Klejborowska, G; Maj, E; Stefańska, J; Wietrzyk, J, 2018
)
2.13
"Monensin is a metal ionophore used as anticancer agent in many types of cancer cells. "( Monensin induces cell death by autophagy and inhibits matrix metalloproteinase 7 (MMP7) in UOK146 renal cell carcinoma cell line.
Das, P; Verma, SP, 2018
)
3.37
"Monensin is a lipid-soluble naturally occurring bioactive ionophore produced by Streptomyces spp. "( Chemotherapeutic Potential of Monensin as an Anti-microbial Agent.
Dutt, S; Ghosh, PC; Ilamathi, HS; Lakshminarayana, TS; Rajendran, V, 2018
)
2.21
"Monensin A (MON) is a polyether ionophore antibiotic, which shows a wide spectrum of biological activity, including anticancer activity. "( Antiproliferative activity of ester derivatives of monensin A at the C-1 and C-26 positions.
Huczyński, A; Jędrzejczyk, M; Klejborowska, G; Maj, E; Stępczyńska, N; Wietrzyk, J, 2019
)
2.21
"Monensin A is an ionophore which selectively complexes and transports sodium cation across lipid membranes, and therefore it shows a variety of biological properties."( Structure and antimicrobial properties of monensin A and its derivatives: summary of the achievements.
Aowicki, D; Huczyński, A, 2013
)
1.38
"Monensin is a widely used feed additive with the potential to minimize methane (CH4) emissions from cattle. "( Anti-methanogenic effects of monensin in dairy and beef cattle: a meta-analysis.
Appuhamy, JA; Dijkstra, J; France, J; Jayasundara, S; Kebreab, E; Strathe, AB; Wagner-Riddle, C, 2013
)
2.12
"Monensin A is a commercially important natural product isolated from Streptomyces cinnamonensins that is primarily employed to treat coccidiosis. "( Jacobsen catalyst as a cytochrome P450 biomimetic model for the metabolism of monensin A.
Assis, Md; Berretta, AA; de Moraes, LA; de Oliveira, AR; Dorta, DJ; Gates, PJ; Lopes, NP; Pazin, M; Peti, AP; Pospíšil, S; Rocha, BA; Rodrigues, AP, 2014
)
2.07
"Monensin is a carrier of cations through lipid membranes capable of exchanging sodium (potassium) cations for protons by an electroneutral mechanism, whereas its ethyl ester derivative ethyl-monensin is supposed to transport sodium (potassium) cations in an electrogenic manner. "( Electrogenic and nonelectrogenic ion fluxes across lipid and mitochondrial membranes mediated by monensin and monensin ethyl ester.
Antonenko, YN; Huczyński, A; Rokitskaya, TI, 2015
)
2.08
"Monensin is a carboxyl polyether ionophore that potently inhibits the growth of various cancer cells. "( Monensin Induces PC-3 Prostate Cancer Cell Apoptosis via ROS Production and Ca2+ Homeostasis Disruption.
Ahn, SC; Kim, KY; Kim, SH; Park, SG; Seo, YK; Yu, HS; Yu, SN, 2016
)
3.32
"Monensin is a feed additive antibiotic that is prevalent throughout the dairy industry and is excreted in dairy waste."( Effects of solid-liquid separation and storage on monensin attenuation in dairy waste management systems.
Bergamaschi, BA; Hafner, SC; Harter, T; Parikh, SJ; Watanabe, N, 2017
)
1.43
"Monensin is an anticoccidial drug that has been used as an additive in medicated feed. "( Evaluation of two liquid chromatography/tandem mass spectrometry platforms for quantification of monensin in animal feed and milk.
Dai, SY; Herrman, TJ, 2010
)
2.02
"Monensin is a polyether ionophore antibiotic that is widely used in the control of coccidia in animals. "( The antibiotic monensin causes cell cycle disruption of Toxoplasma gondii mediated through the DNA repair enzyme TgMSH-1.
Arrizabalaga, G; Lavine, MD, 2011
)
2.16
"Monensin is a carboxylic polyether ionophore used in the poultry industry as a coccidiostat. "( Does monensin in chicken manure from poultry farms pose a threat to soil invertebrates?
Hrženjak, R; Kalcher, GT; Semrov, N; Srimpf, K; Zidar, P; Zižek, S, 2011
)
2.33
"Monensin is an ionophore widely used in the dairy cattle industry throughout the world. "( Overview of meta-analysis of monensin in dairy cattle.
Duffield, TF; Lean, IJ; Rabiee, A, 2012
)
2.11
"Monensin is a common feed additive used in various countries, where 1 of the associated benefits for use in beef cattle is improved efficiency of energy metabolism by the rumen bacteria, the animal, or both. "( Quantifying the effect of monensin dose on the rumen volatile fatty acid profile in high-grain-fed beef cattle.
Archibeque, S; Bannink, A; Dijkstra, J; Ellis, JL; France, J; Hook, SE; Kebreab, E, 2012
)
2.12
"Monensin A is an ionophore able to carry protons and cations through the cell membrane. "( Spectroscopic and semiempirical studies of a proton channel formed by the methyl ester of monensin A.
Bartl, F; Brzezinski, B; Huczyñski, A; Przybylski, P, 2006
)
2
"Monensin thus promises to be a useful tool in the study of intracellular transport in photoreceptors."( Effects of monensin on photoreceptors of isolated frog retinas.
Holtzman, E; Kalff, M; Matheke, ML, 1983
)
1.38
"Monensin is a monovalent ionophore that has been reported to exhibit a high degree of in vitro selectivity to transport Na+ ions."( The effect of monensin, a Na+-selective carboxylic ionophore, on coronary circulation.
Hester, RK; Kabell, GG; Saini, RK; Somani, P, 1980
)
1.34
"Monensin is a polyether antibiotic ionophore and is considered an electroneutral Na/H antiporter. "( Conductance change in phospholipid bilayer membrane by an electroneutral ionophore, monensin.
Inabayashi, M; Jin, T; Kamo, N; Miyauchi, S, 1995
)
1.96
"Monensin is a carboxylic ionophore which perturbs the structure and function of the Golgi apparatus and lysosomes. "( Effect of monensin on DNA synthesis in cultured human thyroid cells.
Itoh, M; Okugawa, T, 1993
)
2.13
"Monensin is an ionophore that supports an electroneutral ion exchange across the lipid bilayer. "( The mechanism of monensin-mediated cation exchange based on real time measurements.
Finkelstein, Y; Gutman, M; Nachliel, E, 1996
)
2.08
"Monensin is a carboxylic ionophore which can potentiate the immunotoxin activity against human tumors in vitro and in vivo. "( A modified HPLC method for monensin analysis in liposomes and nanocapsules and its comparison with spectrophotometric and radioactive methods.
Bennefield, SD; Ferdous, AJ; Singh, M, 1997
)
2.04
"Monensin (1) is a representative compound of polyether ionophore antibiotics, which selectively transport Na+ ions. "( [Transformation of natural products into more potent compounds: chemical modification of monensin].
Nagatsu, A; Sakakibara, J, 1997
)
1.96
"Monensin is a carboxylic ionophore which can potentiate the activity of ricin based immunotoxins (IT) in vitro and in vivo against a variety of human tumours. "( Role of monensin PLGA polymer nanoparticles and liposomes as potentiator of ricin A immunotoxins in vitro.
Ferdous, AJ; Singh, M; Stembridge, NY, 1998
)
2.18
"Monensin is an inhibitor of trans-Golgi function, while BFA inhibits protein transport between the endoplasmic reticulum (ER) and the Golgi."( Brefeldin A, but not monensin, completely blocks CD69 expression on mouse lymphocytes: efficacy of inhibitors of protein secretion in protocols for intracellular cytokine staining by flow cytometry.
Kalies, I; Nylander, S, 1999
)
1.34
"Monensin (MON) is an ionophore antibiotic widely used in veterinary practice as a coccidiostatic or a growth promoter. "( Oxidative metabolism of monensin in rat liver microsomes and interactions with tiamulin and other chemotherapeutic agents: evidence for the involvement of cytochrome P-450 3A subfamily.
Carletti, M; Ceppa, L; Dacasto, M; Nachtmann, C; Nebbia, C, 1999
)
2.05
"Monensin is a ionophore compound with different biological activities. "( The ionophore monensin inhibits mouse polyomavirus DNA replication and destabilizes viral early mRNAs.
Iacoangeli, A; Melucci-Vigo, G; Risuleo, G, 2000
)
2.11
"Monensin is a product of Streptomyces cinnamonensis."( [The effect of monensin on performance and selected biochemical and hematological parameters in the blood of calves].
Machanová, L; Skrivanová, V; Svoboda, T,
)
1.21
"Monensin is a potent secretagogue and the mechanism by which the ensuing elevation of intracellular Na+ concentration might induce a secretory response remains to be determined."( Catecholamine secretion from adrenal chromaffin cells of the toad (Caudiverbera caudiverbera): effect of monensin.
Luxoro, M; Nassar-Gentina, V, 1992
)
1.22
"Monensin is a monovalent metal ionophore that affects the intracellular translocation of secretory proteins at the level of trans-Golgi cisternae. "( Effect of monensin on the sulfation of heparan sulfate proteoglycan from endothelial cells.
Buonassisi, V; Colburn, P; Dietrich, CP; Nader, HB; Sampaio, LO, 1992
)
2.13
"Monensin is an ionophoretic antibiotic, which selectively transports alkali metal cations across biological membranes. "( Effects of monensin on selenium status and related factors in genetically hypo- and hyperselenemic growing swine.
Horvath, CJ; Miller, ER; Stowe, HD, 1992
)
2.12
"Monensin is a carboxylic ionophore that has been observed to increase cation permeability across the membrane of several cell types. "( Monensin-induced cation movements in bovine erythrocytes.
Dixon, E, 1990
)
3.16
"Monensin, which acts as an ionophore on intracellular vesicle compartments inhibited HAV infection probably at the uncoating step."( Effect of cellular function inhibitors on the infection of Frp/3 cells by hepatitis A virus.
Divizia, M; Gabrieli, R; Orsi, N; Panà, A; Seganti, L; Superti, F, 1989
)
1
"Monensin is an effective anticoccidial agent widely used in the poultry industry. "( Thin-layer chromatography/bioautography method for detection of monensin in poultry tissues.
MacNeil, JD; Vanderkop, PA,
)
1.81
"Monensin is a sodium selective carboxylic ionophore that has been helpful in studying the intracellular mechanisms of protein secretion by its ability to inhibit transport of secretory proteins, particularly through the Golgi apparatus, and by its capacity to block intracellular posttranslational processing events. "( Monensin inhibition of corticotropin releasing factor mediated ACTH release.
Shakir, KM; Sobel, DO,
)
3.02
"Monensin is a carboxylic ionophore which dissipates proton gradients across cell membranes. "( Enhancement of the specific cytotoxicity of a breast cancer-associated antigen immunotoxin by the carboxylic ionophore monensin.
Griffin, TW; Houston, LL; Pagnini, PG, 1987
)
1.92
"Monensin is an ionophore which disrupts the structure of the Golgi apparatus and inhibits vesicular transport in eukaryotic cells. "( Monensin stimulates glycerolipid incorporation into rod outer segment membranes.
Basinger, SF; Fliesler, SJ, 1987
)
3.16

Effects

Monensin has been shown to reduce lactic acid production, aid in the control of coccidia and bloat and to be toxic to face and horn fly larva in feces of monensin-fed cattle. Monensin could prevent progression of shock and improve prognosis in management of hemorrhagic hypotension.

ExcerptReferenceRelevance
"Monensin has represented anti-cancer effect on various human cancer cells."( Effect of antibiotic monensin on cell proliferation and IGF1R signaling pathway in human colorectal cancer cells.
Deng, Y; He, TC; Qiao, M; Wang, J; Wei, Q; Yan, Z; Ye, J; Zhang, J; Zhou, Y, 2023
)
1.95
"Monensin has strong antimicrobial properties, attributed to its ability to transport sodium ions across cell membranes."( Mass spectrometric characterization of the seco acid formed by cleavage of the macrolide ring of the algal metabolite goniodomin A.
Gaillard, S; Harris, CM; Harris, TM; Hintze, L; Krock, B; Reece, KS; Small, H; Tanniou, S; Tillmann, U, 2023
)
1.63
"Monensin has potential to be incorporated as one of the main components in an otic formulation."( In vitro antimicrobial activity of monensin against common clinical isolates associated with canine otitis externa.
Chan, WY; Hickey, EE; Hill, PB; Khazandi, M; Page, SW; Trott, DJ, 2018
)
1.48
"Thus monensin has the potential to prevent progression of shock and improving the prognosis in management of hemorrhagic hypotension."( Effect of ionophore monensin on anaesthetized dogs in hemorrhagic hypotension.
Babbar, R; Fahim, M; Gupta, RK, 2005
)
1.11
"Monensin has been tested to determine its toxicity and safety in cattle. "( Monensin toxicity in cattle.
Cooley, CO; Potter, EL; VanDuyn, RL, 1984
)
3.15
"Monensin has also been shown to reduce lactic acid production, aid in the control of coccidia and bloat and to be toxic to face and horn fly larva in feces of monensin-fed cattle."( Influence of monensin on the performance of cattle.
Garrett, JE; Gast, DR; Goodrich, RD; Kirick, MA; Larson, DA; Meiske, JC, 1984
)
1.36
"7 Monensin has widespread, complex, effects on the secretory responses and ion handling by the B cells, which are difficult to interpret in terms solely of actions as a Na+ ionophore."( Effects of monensin on metabolism of isolated rat islets of Langerhans.
Howell, SL; Smith, JE, 1984
)
1.22
"As monensin has been reported to interfere with the Golgi apparatus, our results indicate that glucosylceramide may be synthesized at a site that is separate from the site where further glycosylation occurs."( Effect of drugs and temperature on biosynthesis and transport of glycosphingolipids in cultured neurotumor cells.
Fishman, PH; Miller-Prodraza, H, 1984
)
0.78
"Monensin has been shown to cause nonexocytotic release of catecholamines from adrenal medullary and PC12 cells. "( Monensin and hypo-osmolar medium cause calcium-independent beta-endorphin secretion from melanotropes.
Bäck, N; Soinila, S; Törnquist, K, 2000
)
3.19
"The monensin PKS has also provided fresh insight into general features of catalysis by modular PKSs, in particular into the mechanism of chain initiation."( Engineering of complex polyketide biosynthesis--insights from sequencing of the monensin biosynthetic gene cluster.
Bisang, C; Cortés, J; Frost, E; Hughes-Thomas, ZA; Jones, MA; Kendrew, SG; Leadlay, PF; Lester, JB; Long, PF; McArthur, HA; McCormick, EL; Oliynyk, M; Oliynyk, Z; Stark, CB; Staunton, J; Wilkinson, CJ, 2001
)
1.02
"Monensin has been shown to inhibit the dissociation of internalized asialoorosomucoid (ASOR) from galactosyl (Gal) receptors in hepatocytes (Harford et al., J. "( Monensin inhibits ligand dissociation only transiently and partially and distinguishes two galactosyl receptor pathways in isolated rat hepatocytes.
Oka, JA; Weigel, PH, 1987
)
3.16
"As monensin has been reported to interfere with the flow of molecules from the cis to the trans stacks of the Golgi apparatus, this result highlights at least one subcompartmentalization of ganglioside biosynthesis within the Golgi system."( Modulation of ganglioside biosynthesis in primary cultured neurons.
Sandhoff, K; van Echten, G, 1989
)
0.79

Actions

Monensin did not cause appreciable elevations of cyclic AMP concentrations, induction of an acrosome reaction, or decreases of ATP concentrations. Monensin tended to increase rates of protein and decrease rates of fat deposition in limit-fed cattle. It induced a change (P < .08) in composition of growth.

ExcerptReferenceRelevance
"The monensin-induced increase in [Ca(2+)](i) was abolished by the omission of extracellular Ca(2+) or 1-[beta-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenethyl]-1H-imidazole hydrochloride (SKF-96365, 100-150 microM), and was largely inhibited by Ni(2+) (2-5 mM)."( Monensin causes transient calcium ion influx into mouse splenic lymphocytes in a sodium ion-independent fashion.
Satoh, E; Satoh, K, 2007
)
2.26
"Monensin tended to increase rumen pH (5.89 vs."( Evaluation of nitrogen utilization and the effects of monensin in dairy cows fed brown midrib corn silage.
Gehman, AM; Janicek, BN; Kononoff, PJ; Mullins, CR, 2008
)
1.32
"Monensin also did not cause appreciable elevations of cyclic AMP concentrations, induction of an acrosome reaction, or decreases of ATP concentrations."( The elevation of cyclic AMP concentrations in flagella-less sea urchin sperm heads.
Garbers, DL, 1981
)
0.98
"Monensin was used to produce graded increases in cell Na+ in order to assess the Na+ dependence of the Na+/K+ pump in the intact cell."( Reversible stimulation of the Na+/K+ pump by monensin in cultures of vascular smooth muscle.
Brock, TA; Smith, JB, 1982
)
1.25
"Monensin tended to increase rates of protein and decrease rates of fat deposition in limit-fed cattle, and it induced a change (P < .08) in composition of growth."( Determining effects of monensin on energy value of corn silage diets for beef cattle by linear or semi-log methods.
Byers, FM, 1980
)
1.29
"Monensin did not inhibit the gene expression for the cytokines, thereby excluding the possibility of intervention by secreted molecules."( Thrombin and trypsin induce granulocyte-macrophage colony-stimulating factor and interleukin-6 gene expression in cultured normal human keratinocytes.
Furukawa, F; Takigawa, M; Wakita, H, 1997
)
1.02
"Monensin did not increase the cellular accumulation of L-glucose in muscle indicating that it does not affect the cell membrane integrity."( Effect of monensin on 2-deoxyglucose uptake, the insulin receptor and phosphatidylinositol 3-kinase activity in rat muscle.
Damrau-Abney, A; Elmendorf, JS; Smith, TR; Turinsky, J, 1997
)
1.42
"Monensin blocked the increase in matrix vesicle PKC after 24 h, suggesting the secosteroid-regulated packaging of PKC."( 1alpha,25(OH)2D3 regulates chondrocyte matrix vesicle protein kinase C (PKC) directly via G-protein-dependent mechanisms and indirectly via incorporation of PKC during matrix vesicle biogenesis.
Boyan, BD; Casasola, D; Dean, DD; Larsson, D; Nemere, I; Schwartz, Z; Sylvia, VL, 2002
)
1.04
"Monensin tended to increase glucose total entry rates for both diets and to increase irreversible loss of glucose for the high-roughage diet but the differences were not significant."( Effects of monensin on in vivo rumen propionate production and blood glucose kinetics in cattle.
Herbein, JH; McGilliard, AD; Van Maanen, RW; Young, JW, 1978
)
1.37
"Monensin and nigericin inhibit steroidogenesis at concentrations that have no other observed deleterious effects on glomeulosa cells."( Ionophores for monovalent cations inhibit angiotensin-stimulated aldosteronogenesis.
Elliott, ME; Goodfriend, TL; Hadjokas, NE; Wen, SF, 1990
)
1
"Monensin continued to cause a dose-dependent increase in [Ca2+]i in the absence of extracellular Ca2+, although an approximately 50% reduction was noted at concentrations of greater than 10(-5) M."( Effects of monensin and veratridine on acetylcholine release and cytosolic free Ca2+ levels in cerebrocortical synaptosomes of rats.
Nakazato, Y; Satoh, E, 1991
)
1.39
"Monensin was seen to cause a slight depression in the amount of cytochrome P-450 and cytochrome b5 as well as in the activities of aniline-p-hydroxylase, p-nitrophenol-hydroxylase and p-nitroanisole-O-demethylase."( [The effect of monensin, tiamulin and the simultaneous administration of both substances on the microsomal mixed function oxidases and on the peroxide formation in broilers].
Laczay, P; Lehel, J; Simon, F, 1990
)
1.35
"Monensin prevented the increase in thromboplastin activity at 68 hr as well as at 90-96 hr."( Effect of some drugs on thromboplastin activity in mouse trophoblast cells in vitro and in vivo.
Dalaker, K; Prydz, H, 1986
)
0.99
"Monensin tended to increase acetate and to decrease butyrate in cultures with lactate."( The effect of monensin on in vitro utilization of lactate in the rumen contents.
Bartos, S; Kalacnjuk, GI; Marounek, M; Savka, OG; Simůnek, J, 1989
)
1.36
"Monensin also promotes movement of atrial granules along the microtubules but does not accelerate the release of ANP."( Monensin turns on microtubule-associated translocation of secretory granules in cultured rat atrial myocytes.
Barron, WM; Iida, H; Page, E, 1988
)
2.44
"Monensin was unable to suppress the growth of lactobacilli; therefore, in contrast to tetronasin, monensin added 24 h after the addition of glucose failed to reverse the acidosis."( Effects of the ionophores monensin and tetronasin on simulated development of ruminal lactic acidosis in vitro.
Newbold, CJ; Wallace, RJ, 1988
)
1.3
"Monensin did not cause the release of dopamine beta-hydroxylase from the cells showing that monensin caused the release of catecholamines by a nonexocytotic mechanism."( Monensin-induced influx of 22Na and the release of catecholamines in cultured bovine adrenal medulla cells and isolated chromaffin granules.
Izumi, F; Kobayashi, H; Toyohira, Y; Wada, A; Yanagihara, N, 1986
)
2.44
"Monensin did not inhibit the reversal of the insulin effect per se."( Effects of monensin on insulin processing in adipocytes. Evidence that the internalized insulin-receptor complex has some physiological activities.
Kono, T; Robinson, FW; Smith, MM; Ueda, M, 1985
)
1.38

Treatment

Monensin treatment of tissue resulted in accumulation of TIMPs in all cellular compartments but particularly of TIMP-1 in epithelium. Treatment segregated alpha3-FucT VI from the Golgi apparatus to swollen peripheral vesicles where it was colocalized with beta4-GalT I.

ExcerptReferenceRelevance
"Monensin treatment led to increases in cell volume and reductions in hemoglobin concentration in most blood samples, though the degree of response varied across samples."( Ionophore-mediated swelling of erythrocytes as a therapeutic mechanism in sickle cell disease.
Azul, M; De Souza, DC; Geisness, AC; Higgins, JM; Szafraniec, H; Williams, D; Wood, DK, 2022
)
1.44
"Monensin treatment caused a decreased fibre degradation potential that was observed by the reduced abundance of proteins assigned to fibrolytic bacteria and glycoside hydrolases, sugar transporters and carbohydrate metabolism."( A shift towards succinate-producing Prevotella in the ruminal microbiome challenged with monensin.
Günther, J; Koch, A; Schleicher, L; Seifert, J; Steuber, J; Trautmann, A, 2023
)
1.85
"Monensin treatment period length did not significantly modify the monensin effects in dairy cow or beef steer studies."( Anti-methanogenic effects of monensin in dairy and beef cattle: a meta-analysis.
Appuhamy, JA; Dijkstra, J; France, J; Jayasundara, S; Kebreab, E; Strathe, AB; Wagner-Riddle, C, 2013
)
1.4
"Monensin treatment mimicked the inhibitory effects of statins on EGFR activation and downstream signaling."( Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors.
Corsten, M; Dayekh, K; Dimitroulakos, J; Johnson-Obaseki, S; Sekhon, HS; Villeneuve, PJ; Weberpals, JI, 2014
)
2.57
"Monensin treatment did not affect the prevalence of any IMI (p=0.68) or IMI due to a major pathogen (p=0.11)."( Effect of application of an external teat sealant and/or oral treatment with a monensin capsule pre-calving on the prevalence and incidence of subclinical and clinical mastitis in dairy heifers.
Compton, CW; McDougall, S; Parker, KI; Weir, AM, 2008
)
1.29
"Monensin treatment was randomly allocated in a crossover design where monensin was supplemented to the lactating dairy cow diet for a consecutive 12-wk period."( A randomized herd-level field study of dietary interactions with monensin on milk fat percentage in dairy cows.
Bagg, R; Baril, J; Brodeur, M; DesCôteaux, L; Dubuc, J; Duffield, T; DuTremblay, D, 2009
)
1.31
"Monensin treatment for 6 h activated caspase-3, -7 and poly(ADP-ribose) polymerase (PARP), inducing apoptosis."( Effect of ionic stress on apoptosis and the expression of TRPM2 in human olfactory neuroepithelial-derived progenitors.
El-Mallakh, RS; Gao, Y; Lei, Z; Lu, C; Roisen, FJ, 2010
)
1.08
"Monensin treatment for 24 h decreased expression of the long form of TRPM2, and increased expression of the short form."( Effect of ionic stress on apoptosis and the expression of TRPM2 in human olfactory neuroepithelial-derived progenitors.
El-Mallakh, RS; Gao, Y; Lei, Z; Lu, C; Roisen, FJ, 2010
)
1.08
"Monensin treatment results autophagy, as shown by translocation of ATG8 to autophagosomes, as well as causing marked morphological changes in the parasites' mitochondria."( Analysis of monensin sensitivity in Toxoplasma gondii reveals autophagy as a mechanism for drug induced death.
Arrizabalaga, G; Lavine, MD, 2012
)
1.48
"In monensin-treated CA46 cells, increased p21-CDK2, p27-CDK2 and p27-CDK4 complex forms were observed."( Monensin-mediated growth inhibition in human lymphoma cells through cell cycle arrest and apoptosis.
Im, YH; Jung, CW; Kang, WK; Kim, BK; Kim, ES; Lee, YY; Park, WH; Seol, JG, 2002
)
2.27
"Monensin premix-treated cows were observed to have increased milk yield, largely as a result of a higher dry matter intake in monensin-treated cows compared to control cows."( Effects of a monensin controlled-release capsule or premix on attenuation of subacute ruminal acidosis in dairy cows.
Bagg, R; Dick, P; Duffield, TF; McBride, BW; Mutsvangwa, T; Plaizier, JC; Vessie, G; Walton, JP, 2002
)
1.41
"Monensin-treated cows had significantly decreased NEFA and BHBA and significantly increased concentrations of serum cholesterol and urea in the week immediately precalving."( Effect of a monensin controlled release capsule on metabolic parameters in transition dairy cows.
Bagg, R; Dick, P; Duffield, TF; LeBlanc, S; Leslie, K; Ten Hag, J, 2003
)
1.42
"Monensin treatment of Leydig cells prevented the recycling of insulin receptors to the cell surface and thereby suppressed the surface binding and enhanced the internalized 125I-insulin."( The role of luteinizing hormone and prolactin in the regulation of insulin receptors in Leydig cells of the adult rat.
Arunakaran, J; Balasubramanian, K; Julie, PM; Malini, T, 2003
)
1.04
"In monensin-treated muscles, inhibition of external Ca2+ influx from the incubation medium by chelation with 1,2 bis(2-aminophenoxy)ethane-N,N,N',N' tetracetic acid (5 mM) markedly reduced 45Ca2+ uptake (38%: P < 0.05) but increased CK release by 85% (P < 0.001)."( The role of sodium ions in the pathogenesis of skeletal muscle damage in broiler chickens.
Mitchell, MA; Sandercock, DA, 2004
)
0.84
"In monensin (250 nM)-treated RNase-L(+/+) cells the average half-life of mt-mRNA, determined after termination of transcription with actinomycin D, was found to be 3h, whereas in monensin-treated RNase-L(-/-) cells the half-life of mt-mRNA was >6h."( RNase-L regulates the stability of mitochondrial DNA-encoded mRNAs in mouse embryo fibroblasts.
Chandrasekaran, K; Hassel, B; Li, XL; Mehrabian, Z, 2004
)
0.84
"Monensin CRC treatment was associated with increased haptoglobin concentrations in clinically unhealthy cattle, perhaps reflecting a better ability to respond to disease challenge."( The impact of controlled release capsules of monensin on postcalving haptoglobin concentrations in dairy cattle.
Bagg, R; Crawford, RG; Dick, CP; Duffield, TF; Leslie, KE, 2005
)
1.31
"The monensin treatment had similar effect on FA metabolism as the oil treatment in comparison to unincubated control."( Effect of sunflower, linseed and fish oils on the production of trans fatty acids in vitro.
Cieslak, A; Jalc, D; Potkanski, A; Szumacher-Strabel, M,
)
0.61
"Monensin treatment also resulted in marked degenerative changes in the histoarchitecture of testis, such as depletion of different germ cell populations, vacuole formation and disorganization of seminiferous tubules."( Effect of monensin, a Na+-specific carboxylic ionophore on the oxidative defense system in rat testis.
Kalla, NR; Sanyal, SN; Singh, M,
)
1.26
"Monensin-treated influenza virus-infected MDCK cells also contain dilated cytoplasmic vesicles, but virus particles were not found in these structures, and numerous influenza virions were observed budding at the cell surface."( Differential effect of monensin on enveloped viruses that form at distinct plasma membrane domains.
Alonso, FV; Compans, RW, 1981
)
1.29
"Monensin treatment results in the accumulation of a 189K antigen which is converted to the mature 236K MA after a 2 hr chase in the absence of monensin."( Glycosylation pathways of two major Epstein-Barr virus membrane antigens.
Adams, MR; Rabin, H; Strnad, BC, 1983
)
0.99
"Monensin treatment of the cells inhibited procollagenase secretion and led to intracellular accumulation of the proenzyme."( Biosynthesis and secretion of procollagenase by rabbit synovial fibroblasts. Inhibition of procollagenase secretion by monensin and evidence for glycosylation of procollagenase.
Brinckerhoff, CE; Harris, ED; Nagase, H; Vater, CA, 1983
)
1.2
"Monensin treatment (10 microM, 4 h) resulted in accumulation of laminin in the Golgi region, located using labeled wheat germ agglutinin."( Laminin is produced by early rat astrocytes in primary culture.
Dahl, D; Liesi, P; Vaheri, A, 1983
)
0.99
"In monensin-treated cells, on the other hand, only 55% of the haemagglutinin had reached the plasma membrane after 90 min of chase, while 94% had arrived there after 180 min of chase."( Effects of monensin on the processing and intracellular transport of influenza virus haemagglutinin in infected MDCK cells.
Edwardson, JM, 1984
)
1.17
"In monensin-treated epididymides, radioactive material accumulated in the Golgi region while the normal increase in labeling of the apical surface and the lumen was completely inhibited for at least 2 hours."( The secretory pathway in the mouse epididymis as shown by electron microscope radioautography of principal cells exposed to monensin.
Flickinger, CJ; Gray, HD; Wilson, KM, 1984
)
0.99
"Monensin-treated calves developed anorexia, diarrhea, and lethargy after day 1."( Clinical, clinicopathologic, and pathologic alterations in acute monensin toxicosis in cattle.
Amstutz, HE; Ferrans, VJ; Rebar, AH; Van Vleet, JF; Weirich, WE, 1983
)
1.23
"Monensin treatment did not affect the synthesis of vaccinia glycoproteins but did significantly reduce the transport of these glycoproteins to the cell surface and also reduced the secretion of proteins."( The effect of cytochalasin D and monensin on enveloped vaccinia virus release.
Kristensson, K; Payne, LG, 1982
)
1.27
"Monensin-treated cells contain many cytoplasmic vesicles."( Monensin depletes PC12 pheochromocytoma cells of catecholamines and of chromaffin-type granules.
Kwan, PW; Perlman, RL; Sheard, BE; Tischler, AS, 1982
)
2.43
"Monensin treatment groups were fed the same amount of the identical ration over the 448-day experiment."( Effects of monensin fed to replacement dairy heifers during the growing and gestation period upon growth, reproduction, and subsequent lactation.
Baile, CA; Chalupa, WV; McLaughlin, CL; Pendlum, LC; Potter, EL; Snyder, DL, 1982
)
1.38
"The monensin treatments and the adjustments in feed intake associated with them had no apparent effect on (1) calf birth weights, (2) adjusted 205-day weaning weights or (3) first-service conception rates for the cows."( Efficacy of monensin for beef cows.
Cmarik, GF; Walker, PM; Weichenthal, BA, 1980
)
1.12
"Monensin treatments consisted of 0, 50, 200 and 300 mg per head per day."( Effect of various levels of monensin on efficiency and production of beef cows.
Raleigh, RJ; Turner, HA; Young, DC; ZoBell, D, 1980
)
1.28
"Monensin treatment significantly increased milk yield in one of the six herds."( Effects of sodium monensin on reproductive performance of dairy cattle. I. Effects on conception rates, calving-to-conception intervals, calving-to-heat and milk production in dairy cows.
Curtis, M; Dyson, R; Lean, IJ; Lowe, B, 1994
)
1.34
"Monensin treatment significantly elevated the level of immature APP."( Inhibitors of endocytosis, endosome fusion, and lysosomal processing inhibit the intracellular proteolysis of the amyloid precursor protein.
Dash, PK; Moore, AN, 1993
)
1.01
"Monensin treatment of tissue resulted in accumulation of TIMPs in all cellular compartments but particularly of TIMP-1 in epithelium."( Tissue inhibitor of metalloproteinases (TIMP)-1, -2 and -3 in human endometrium during the menstrual cycle.
Salamonsen, LA; Zhang, J, 1997
)
1.02
"Monensin treatment significantly reduced serum beta-hydroxy-butyrate concentrations at wk 1, 2, and 3 postpartum and significantly raised serum glucose concentrations during wk 1 and 2 of lactation."( Effect of prepartum administration of monensin in a controlled-release capsule on postpartum energy indicators in lactating dairy cows.
Bagg, R; Dick, P; Duffield, TF; Leslie, KE; Lissemore, K; Lumsden, JH; McBride, BW; Sandals, D, 1998
)
1.29
"Monensin treatment significantly reduced the incidence of subclinical ketosis when the threshold was defined using higher concentrations of serum beta-hydroxybutyrate (1400 and 2000 mumol/L)."( Efficacy of monensin for the prevention of subclinical ketosis in lactating dairy cows.
Bagg, R; Dick, P; Duffield, TF; Leslie, KE; Lissemore, K; Lumsden, JH; McBride, BW; Sandals, D, 1998
)
1.4
"Monensin treatment segregated alpha3-FucT VI from the Golgi apparatus to swollen peripheral vesicles where it was colocalized with beta4-GalT I while alpha2,6(N)sialyltransferase remained associated with the Golgi apparatus."( alpha1,3Fucosyltransferase VI is expressed in HepG2 cells and codistributed with beta1,4galactosyltransferase I in the golgi apparatus and monensin-induced swollen vesicles.
Berger, EG; Borsig, L; Höchli, M; Imbach, T, 1999
)
1.23
"Monensin treatment tended to reduce the incidence of clinical ketosis (P = 0.11) and the risk of being culled (P = 0.09) in the first 94 d of lactation."( Effect of a monensin-controlled release capsule on cow health and reproductive performance.
Bagg, R; Dick, P; Duffield, TF; Leslie, KE; Lissemore, K; Lumsden, JH; McBride, BW; Sandals, D, 1999
)
1.4
"Monensin treatment significantly decreased the ruminal molar proportions of acetic acid (P < 0.10) and butyric acid (P < 0.001) and increased the molar proportions of propionic acid (P < 0.001) and minor VFA (P < 0.01)."( The effect of season and monensin sodium on the digestive characteristics of autumn and spring pasture fed to sheep.
Burnham, DL; France, J; Lynch, GA; Maas, JA; McCutcheon, SN; Wilson, GF, 2001
)
1.34
"The monensin- and BLIS-treated cultures eventually grew rapidly and did not lag a second time."( The adaptation and resistance of Clostridium aminophilum F to the butyrivibriocin-like substance of Butyrivibrio fibrisolvens JL5 and monensin.
Russell, JB; Rychlik, JL, 2002
)
1
"Monensin-treated calves were free of clinical signs of coccidiosis, but inoculated control calves developed diarrhea and had excessive oocyst discharge on days 19 to 28 after they were inoculated."( Monensin for the prevention of coccidiosis in calves.
McDougald, LR, 1978
)
2.42
"Monensin treated neurons also exhibited dilation of the Golgi cisternae."( Contributions of sodium and chloride to ultrastructural damage after dendrotomy.
Emery, DG; Gross, GW; Lucas, JH, 1991
)
1
"Monensin treatment to block recycling also failed to reveal any internally accumulated."( Lack of detectable endocytosis of B lymphocyte MHC class II antigens using an antibody-independent technique.
Cresswell, P; Davis, JE, 1990
)
1
"Monensin-treated cells demonstrated morphological changes in the Golgi complex and secreted enzyme with an altered electrophoretic mobility: two discrete bands of approximately 95 and 110 kDa were found, as compared to the heterodisperse nature of the enzyme from untreated controls."( Golgi-mediated post-translational processing of secretory acid phosphatase by Leishmania donovani promastigotes.
Bates, PA; Dwyer, DM; Hermes, I, 1990
)
1
"In monensin-treated cells a pronounced increase in enzyme activity was found, whereas the secreted activity was markedly reduced."( Intracellular regulation of lipoprotein lipase in human monocyte-derived macrophages.
Blomhoff, JP; Letnes, H; Stray, N, 1990
)
0.79
"Monensin treatment of the heat-induced cells prevented autophosphorylation of the mature PDGF receptor and also prevented subsequent induction of c-fos."( Autocrine stimulation by the v-sis gene product requires a ligand-receptor interaction at the cell surface.
Donoghue, DJ; Hannink, M, 1988
)
1
"Monensin treatment alone (1 x 10(-6) M) results in the Golgi complexes of the tegumental cells becoming very diffuse from 1.5 h onwards, and relatively few secretory bodies are present in the cytoplasm."( Fasciola hepatica: the effect of the sodium ionophore monensin on the adult tegument.
Fairweather, I; Skuce, PJ, 1989
)
1.25
"Monensin treatment resulted in the accumulation of a 165-kD molecule which was judged to be a precursor of gp350/220."( Intracellular synthesis of Epstein-Barr virus membrane antigen gp350/220. Inhibitory effect of monensin on its expression.
Bertoni, G; Humphreys, RE; Nguyen, QV; Sairenji, T, 1989
)
1.22
"Monensin (1 microM) treatment also resulted in a reduction in syncytium formation, which was observed when recombinant infected cells were cocultivated with CD4-bearing HeLa cells."( Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: effects of monensin on glycosylation and transport.
Dewar, RL; Natarajan, V; Salzman, NP; Vasudevachari, MB, 1989
)
1.21
"Monensin treatment resulted in the dilatation of the Golgi apparatus and caused the appearance of numerous intracellular lumina lined with microvilli in associated as well as isolated hepatocytes but did not modify newly formed bile canaliculi."( The effects of monensin on the transport of horseradish peroxidase into intracellular lumina in cultured rat hepatocytes.
Gérolami, A; Hashieh, IA; Mathieu, S; Rémy, L, 1989
)
1.35
"Monensin treatment of the tumor cells led to a 95% inhibition of sulfation with the accumulation of unsulfated trisaccharide GlcNAc beta 1,6-(Gal beta 1,3)-GalNAc and sialylated derivative GlcNAc beta 1,6-(NeuAc alpha 2,3-Gal beta 1,3)-GalNAc."( Sulfation of the tumor cell surface sialomucin of the 13762 rat mammary adenocarcinoma.
Carraway, KL; Hull, SR, 1989
)
1
"Monensin treatment produced large, Golgi-derived vacuoles which were isolated using Percoll density centrifugation and identified by electron microscopy."( Biochemical and ultrastructural effects of monensin on the processing, intracellular transport, and packaging of myeloperoxidase into low and high density compartments of human leukemia (HL-60) cells.
Akin, DT; Kinkade, JM; Parmley, RT, 1987
)
1.26
"Monensin treatment at 100 microM caused the loss of surface receptors with a t1/2 of 3 h and the accumulation of internalized ligand in a "pre-lysosomal" endocytic compartment."( Receptor-mediated endocytosis in Xenopus oocytes. I. Characterization of the vitellogenin receptor system.
Opresko, LK; Wiley, HS, 1987
)
0.99
"Monensin-treated cells had less lysosomal cathepsin D and relatively more microsomal enzyme."( Alterations of the posttranslational processing of a lysosomal enzyme in C6 glioma cells.
Snyder, DS; Whitaker, JN, 1988
)
1
"Monensin treatment of biopsies resulted in the modification of the Mr-160,000 species to the Mr-140,000 molecule, which was endo-H sensitive."( Biosynthesis and maturation of lactase-phlorizin hydrolase in the human small intestinal epithelial cells.
Lentze, MJ; Naim, HY; Sterchi, EE, 1987
)
0.99
"In monensin-treated cells, the conversion of intracellular proenzymes to mature enzymes was significantly inhibited and the proenzymes were secreted into the medium."( Biosynthesis of lysosomal cathepsins B and H in cultured rat hepatocytes.
Amano, J; Kato, K; Nishimura, Y; Sato, H; Tsuji, H, 1988
)
0.79
"Monensin treatment resulted in morphologically abnormal endosomes, while pepstatin only inhibited VTG cleavage and the subsequent fusion of endosomes with yolk platelets."( Specific proteolysis regulates fusion between endocytic compartments in Xenopus oocytes.
Karpf, RA; Opresko, LK, 1987
)
0.99
"Free monensin, obtained by treatment with phosphate buffer solution (pH 3) at 0 degrees C, is derivatized with ADAM and passed through a disposable silica cartridge."( Liquid chromatographic determination of monensin in chicken tissues with fluorometric detection and confirmation by gas chromatography-mass spectrometry.
Suzuki, S; Takatsuki, K; Ushizawa, I,
)
0.85
"Monensin treatment decreased protozoal numbers and microbial activity, as evidenced by lower gas production from in vitro fermentation of ground alfalfa hay when compared to pretreatment."( Ruminal changes in monensin- and lasalocid-fed cattle grazing bloat-provocative alfalfa pasture.
Fina, LR; Katz, MP; Nagaraja, TG, 1986
)
1.32
"Monensin treatment decreased first pass uptake of 125I-ASOR to 57% and abruptly blocked the release of radioactivity into the perfusate and the bile."( Effects of monensin on vesicular transport pathways in the perfused rat liver.
Brown, WR; Kloppel, TM; Reichen, J, 1986
)
1.38
"The monensin-treated cells degraded pulse-labeled newly synthesized collagen nearly twice as long as the controls, resulting in an overall increase in the fraction of newly synthesized collagen that was degraded."( Decreased synthesis and increased intracellular degradation of newly synthesized collagen in freshly isolated chick tendon cells incubated with monensin.
Berg, RA; Neblock, DS, 1986
)
0.95
"Monensin treatment of the cells favours the intracytoplasmic accumulation of products at various glycosylation stages."( Characterization of C1q, C1s and C-1 Inh synthesized by stimulated human monocytes in vitro.
Bensa, JC; Colomb, MG; Prandini, MH; Reboul, A, 1985
)
0.99
"Monensin-treated cells synthesize fully active lipoprotein lipase."( Maturation and secretion of lipoprotein lipase in cultured adipose cells. I. Intracellular activation of the enzyme.
Ailhaud, G; Amri, EZ; Etienne, J; Négrel, R; Vannier, C, 1985
)
0.99
"Monensin treatment (200 nM) enabled the post-translational processing of newly synthesized dopamine beta-hydroxylase, from the 77,000-Mr to the 73,000-Mr subunit form, to go to completion."( Effect of monensin on synthesis, post-translational processing, and secretion of dopamine beta-hydroxylase from PC12 pheochromocytoma cells.
Hadman, M; Kuhn, LJ; Sabban, EL, 1986
)
1.39
"Monensin treatment inhibited the cleavage of F0 over an 80 min chase period, indicating that this occurred late in the transit of F0 through the Golgi apparatus or after exit from the Golgi apparatus."( Kinetics of synthesis of respiratory syncytial virus glycoproteins.
Cote, PJ; Dapolito, G; Fernie, BF; Gerin, JL, 1985
)
0.99
"Pretreatment with monensin and bafilomycin A1, which also have lysosome inhibition activity, significantly decreased OATP1B1-mediated transport in HEK293-OATP1B1 cells."( Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions.
Abuznait, AH; Alam, K; Ding, K; Li, L; Pahwa, S; Wang, X; Yue, W; Zhang, P, 2016
)
0.76
"Cows treated with monensin boluses had a significantly lower humoral immune response than cows treated with placebo boluses at one time point post-challenge (week 4 post-challenge)."( Monensin use against Neospora caninum challenge in dairy cattle.
Acorn, A; Clark, F; Greenwood, S; Markham, F; McCarron, J; O'Handley, R; VanLeeuwen, JA, 2011
)
2.14
"Treatment with monensin for 72 h decreased CDK4 and cyclin A levels in CA46 cells, and cdc2 levels in Molt-4 cells."( Monensin-mediated growth inhibition in human lymphoma cells through cell cycle arrest and apoptosis.
Im, YH; Jung, CW; Kang, WK; Kim, BK; Kim, ES; Lee, YY; Park, WH; Seol, JG, 2002
)
2.1
"Treatment with monensin significantly increased body condition score at calving in multiparous cows."( Effect of a monensin controlled-release capsule on rumen and blood metabolites in Florida Holstein transition cows.
Archbald, LF; Donovan, GA; Goff, JP; Littell, R; Melendez, P; Risco, CA, 2004
)
1.04
"Cows treated with monensin were 0.68 times less likely to give a positive result for milk BHBA than non-treated cows (0.53-0.80; 95% CI)."( Incidence of subclinical ketosis in cows supplemented with a monensin controlled-release capsule in Holstein cattle, Florida, USA.
Archbald, LF; Donovan, GA; Goff, JP; Littell, R; Melendez, P; Risco, CA, 2006
)
0.9
"Cows treated with monensin were 2.1 times as likely to develop dystocia and 0.8 times as likely to develop metritis as control cows. "( Effect of administration of a controlled-release monensin capsule on incidence of calving-related disorders, fertility, and milk yield in dairy cows.
Archbald, LF; Donovan, GA; Goff, JP; Littell, RC; Melendez, P; Risco, CA, 2006
)
0.92
"Treatment with monensin caused accumulation in the cell of a form of G1 with partial sensitivity toward endo H, suggesting that monensin may act to inhibit the glycosylation process directly."( A membrane glycoprotein that accumulates intracellularly: cellular processing of the large glycoprotein of LaCrosse virus.
Lenard, J; Madoff, DH, 1982
)
0.6
"Treatment with monensin (1 microM) prevented the secretion of the 89K pseudorabies virus-induced sulphated glycoprotein."( The effect of monensin on virion production and protein secretion in pseudorabies virus-infected cells.
Kerr, CL; Pennington, TH, 1984
)
0.97
"Treatment with monensin, a secretory protein transport inhibitor, uniformly increased activity in the rough endoplasmic reticulum while causing marked dilatation of the intensely positive Golgi cisternae."( Alkaline phosphatase biosynthesis in the endoplasmic reticulum and its transport through the Golgi apparatus to the plasma membrane: cytochemical evidence.
Fishman, WH; Tokumitsu, S, 1983
)
0.61
"By treatment with monensin or brefeldin A, the mature mucin was not secreted extracellularly."( Biosynthesis of mucin derived from a 60-kDa precursor protein in the human stomach.
Okazaki, K; Sano, S; Slomiany, A; Slomiany, BL; Yamamoto, Y, 1994
)
0.61
"Pretreatment with monensin at a concentration lower than that eliciting the action resulted in a potentiation of Hi-induced depolarization."( The role of ions on histamine-induced depolarization in isolated guinea pig adipocytes.
Kamei, C; Sugimoto, Y, 1994
)
0.61
"Treatment with monensin or ammonium chloride partially inhibited virus release from Caco-2 cells."( Vectorial release of poliovirus from polarized human intestinal epithelial cells.
Compans, RW; Thornton, CL; Tucker, SP; Wimmer, E, 1993
)
0.63
"Treatment with monensin did not significantly alter the risk of any disease."( Effects of monensin on the reproduction, health, and milk production of dairy cows.
Beckett, S; Dyson, R; Lean, I; Tranter, W; Wade, L, 1998
)
1.03
"Treatment with monensin increased milk production, but this effect was dependent on body condition score prior to calving."( Effect of prepartum administration of monensin in a controlled-release capsule on milk production and milk components in early lactation.
Bagg, R; Dick, P; Duffield, TF; Leslie, KE; Lissemore, K; Lumsden, JH; McBride, BW; Sandals, D, 1999
)
0.91
"Treatment with monensin significantly reduced the incidence of abomasal displacement (OR = 0.41-0.84) and multiple illnesses (OR = 0.38-0.89)."( Effect of a monensin-controlled release capsule on cow health and reproductive performance.
Bagg, R; Dick, P; Duffield, TF; Leslie, KE; Lissemore, K; Lumsden, JH; McBride, BW; Sandals, D, 1999
)
1.02
"Treatment with monensin also reduced the activity of carboxypeptidase E, which is one of the proteolytic processing enzymes of neuropeptides."( Effect of monensin on the levels of tachykinins and their processing enzyme activity in rat dorsal root ganglia.
Chikuma, T; Hojo, H; Inomata, Y; Kato, T; Tsuchida, K, 2002
)
1.06
"Pretreatment with monensin inhibited the turnover of the surface EGF receptor pool by 50-60% within 10 min and blocked the temperature-dependent externalization of receptors."( Rapid constitutive internalization and externalization of epidermal growth factor receptors in isolated rat hepatocytes. Monensin inhibits receptor externalization and reduces the capacity for continued endocytosis of epidermal growth factor.
Christoffersen, T; Gladhaug, IP, 1988
)
0.81

Toxicity

Monensin is extremely toxic to some domestic animals, like the equine species, if they ingest poultry or cattle rations containing the drug. The heart and probably the liver are sensitive indicators of monensin toxicity.

ExcerptReferenceRelevance
" The LD50 was estimated to be between 2 and 3 mg/kg of body weight."( Evaluation of monensin toxicity in the horse.
Matsuoka, T, 1976
)
0.62
" HSA-Mo was 2-13-fold less toxic than Mo for cells in vitro."( Carrier protein-monensin conjugates: enhancement of immunotoxin cytotoxicity and potential in tumor treatment.
Chignola, R; Colombatti, M; Dell'Arciprete, L; Tridente, G, 1990
)
0.63
" Concurrent administration of monensin sodium at a constant safe dosage enhanced the toxicity of selenium as demonstrated by increased severity of the signs of intoxication, fatalities, tissue selenium concentrations and intensified gross, histopathological and histochemical changes."( Effects of concurrent oral administration of monensin on the toxicity of increasing doses of selenium in lambs.
Barlow, RM; Humphreys, DJ; Robins, M; Smyth, JB; Stodulski, JB; Wang, JH, 1990
)
0.83
" These results indicate that measurement of cellular ATP content would be a useful method forecasting the intrarenal toxic site and potency of possible nephrotoxic chemical compounds."( Nephrotoxicity assessment by measuring cellular ATP content. I. Substrate specificities in the maintenance of ATP content in isolated rat nephron segments.
Endou, H; Jung, KY; Uchida, S, 1989
)
0.28
"Monensin is extremely toxic to some domestic animals, like the equine species, if they ingest poultry or cattle rations containing the drug."( Effects of some calcium modulators on monensin toxicity.
Martin, T; Mitema, ES; Sangiah, S, 1988
)
1.99
"Five 7-day trials using 336, 24, 24, 40, and 40 Large White male turkeys when 7, 11, 15, 27, and 32 weeks of age, respectively, were conducted to determine the toxic effects of salinomycin."( Salinomycin toxicity in turkeys.
Blair, ME; Blake, JP; Bliss, BA; Denbow, DM; Potter, LM, 1986
)
0.27
" The results show that the heart and probably the liver are sensitive indicators of monensin toxicity and that the subchronic toxic dose is less than 18 mg/kg body weight per day."( Subchronic toxicity of monensin in broiler chickens.
Bradley, BD; Furrow, RD; Wagner, DD, 1983
)
0.8
" Our conclusions: BAC, VIR and AVO do not counteract the toxic effect of monensin."( Effect of growth promoters on monensin toxicity in broiler chicks.
Bartov, I, 1994
)
0.81
"The characteristics of the toxic interaction between monensin and tiamulin were investigated in rats."( Studies on the toxic interaction between monensin and tiamulin in rats: toxicity and pathology.
Bajnógel, J; Laczay, P; Móra, Z; Szücs, G; Varga, A, 2000
)
0.82
" These data reveal the synergistic effect between two dietary molecules, otherwise per se toxic at much higher concentrations, with possible implications for human and animal health."( Studies on the joint cytotoxicity of Wheat Germ Agglutinin and monensin.
Andrighetto, G; Chignola, R; Dalla Pellegrina, C; Matucci, A; Peruffo, AD; Rizzi, C; Veneri, G; Vincenzi, S; Zoccatelli, G, 2004
)
0.56
" DMSA has considerably lower toxicity than the classic heavy metal antagonist BAL (2,3-dimercaptopropanol) and is also less toxic than DMPS."( Metal chelators and neurotoxicity: lead, mercury, and arsenic.
Aaseth, J; Bjørklund, G; Mutter, J, 2017
)
0.46

Pharmacokinetics

A liquid chromatography-tandem mass spectrometric method was developed and validated for use in pharmacokinetic studies. The method was used to determine the concentrations of monensin in plasma and edible tissues of chicken.

ExcerptReferenceRelevance
" The aim of the present study was to investigate the contribution of lysosomal trapping to the total tissue uptake of perazine, and the pharmacokinetic interaction between the neuroleptic and antidepressants."( Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants.
Daniel, WA; Wójcikowski, J, 1999
)
0.3
"A liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed and validated for use in pharmacokinetic studies in order to determine the concentrations of monensin in plasma and edible tissues of chicken."( Liquid chromatography-electrospray tandem mass spectrometric method for quantification of monensin in plasma and edible tissues of chicken used in pharmacokinetic studies: applying a total error approach.
Abjean, JP; Chéneau, E; Henri, J; Laurentie, M; Pirotais, Y; Roudaut, B; Sanders, P, 2007
)
0.75
"We developed a flow-limited physiologically based pharmacokinetic model for residues of monensin in chickens and evaluated its predictive ability by comparing it with an external data set describing concentration decays after the end of treatment."( A physiologically based pharmacokinetic model for chickens exposed to feed supplemented with monensin during their lifetime.
Carrez, R; Henri, J; Laurentie, M; Méda, B; Sanders, P, 2017
)
0.9

Compound-Compound Interactions

The current study has demonstrated that by suitable adjustment of charge, density, and chain length of PEG on the surface of liposomes it would be possible to direct liposomal ricin to human tumor cells for their selective elimination.

ExcerptReferenceRelevance
" Four feeding trials were conducted to determine the performance of turkey poults when these compounds were used singly or in combination with 100 ppm of furazolidone."( Effect of including lasalocid or monensin singly or in combination with furazolidone on the growth and feed consumption of turkey poults.
Czarnecki, CM, 1990
)
0.56
"Three trials were conducted with finishing steers to study the effect of feeding sorbitol alone or combined with monensin."( Feeding sorbitol alone or in combination with monensin to finishing cattle.
Fontenot, JP; Huchette, HM, 1993
)
0.76
" The current study has demonstrated that by suitable adjustment of charge, density, and chain length of PEG on the surface of liposomes it would be possible to direct liposomal ricin to human tumor cells for their selective elimination in combination with monensin."( Enhanced killing of human epidermoid carcinoma (KB) cells by treatment with ricin encapsulated into sterically stabilized liposomes in combination with monensin.
Ghosh, PC; Rathore, SS; Tyagi, N, 2011
)
0.75
" schidigera (YE) alone and in combination with MON were assessed on ruminal microbial composition and fermentation in vitro of a barley-based diet."( Effects of extracts of Humulus lupulus (hops) and Yucca schidigera applied alone or in combination with monensin on rumen fermentation and microbial populations in vitro.
McAllister, T; Narvaez, N; Wang, Y, 2013
)
0.6
"001) with addition of MON (10 µg mL(-1)) and combined with HE or YE."( Effects of extracts of Humulus lupulus (hops) and Yucca schidigera applied alone or in combination with monensin on rumen fermentation and microbial populations in vitro.
McAllister, T; Narvaez, N; Wang, Y, 2013
)
0.6
" Monensin in long-circulating liposomes of stearylamine with 5 mol% DSPE-mPEG 2000 in combination with free artemisinin resulted in enhanced killing of parasites, prevented parasite recrudescence, and improved survival."( Stearylamine Liposomal Delivery of Monensin in Combination with Free Artemisinin Eliminates Blood Stages of Plasmodium falciparum in Culture and P. berghei Infection in Murine Malaria.
Dutt, S; Ghosh, PC; Hasan, GM; Rajendran, V; Raza, M; Rohra, S, 2015
)
1.6
"The objective of this research was to use data from multiple studies to comprehensively quantify the effects of feeding 1) laidlomycin propionate (LP), alone and/or in combination with chlortetracycline, compared with 2) monensin sodium (MS), alone and/or in combination with tylosin, at commercially approved dosages, on ADG, DMI, feed efficiency (FE), mortality, and carcass characteristics (HCW and liver abscesses)."( Meta-analysis of the effects of laidlomycin propionate, fed alone or in combination with chlortetracycline, compared with monensin sodium, fed alone or in combination with tylosin, on growth performance, health, and carcass outcomes in finishing steers in
Branine, M; Cernicchiaro, N; Corbin, M; Prouty, F; Quinn, M; Renter, DG, 2016
)
0.83
" aureus ATCC 29213 when narasin or monensin were combined with NAC."( In vitro antimicrobial activity of narasin and monensin in combination with adjuvants against pathogens associated with canine otitis externa.
Chan, WY; Hickey, EE; Hill, PB; Khazandi, M; Page, SW; Trott, DJ, 2020
)
1.09
" Previous work feeding monensin (MON) in combination with an oregano, prebiotic, and cobalt-lactate (EOC) blend had demonstrated improved calf gut health and growth performance."( Feeding a calf starter containing monensin alone or in combination with an oregano, and cobalt blend to Holstein calves.
Bai, Y; Casper, DP; Chen, H; Guo, J; Liu, T; Wu, J, 2020
)
1.15

Bioavailability

Monensin inhibited the degradation of atrazine, changed the metabolite patterns in soil and increased the bioavailability of earthworms. Chronic Cu poisoning could be accelerated by dietary supplements of monensin in sheep without ruminal microfauna.

ExcerptReferenceRelevance
" It was concluded that chronic Cu poisoning could be accelerated by dietary supplements of monensin in sheep without ruminal microfauna, and the dietary Cu bioavailability could be decreased by dietary supplements of bentonite in sheep with a normal population of protozoa in the rumen."( Effects of bentonite and monensin on selected elements in the stomach and liver of fauna-free and faunated sheep.
Dayrell, Mde S; Hidiroglou, M; Ivan, M, 1992
)
0.81
"A bioavailability study was conducted in lambs following intravenous and oral administration of sodium selenite (0."( Effects of monensin on the bioavailability and elimination of selenium from blood in lambs.
Humphreys, DJ; Middleton, DJ; Wang, JH, 1990
)
0.67
" Magnesium oxide appeared to have higher Mg bioavailability than MgSO4 for cows precalving, but Mg bioavailability was not different postcalving."( Performance, blood and ruminal characteristics of cows receiving monensin and a magnesium supplement.
Grings, EE; Males, JR, 1988
)
0.51
" The pharmacokinetics of monensin, including half-life, apparent volume of distribution, total body clearance, systemic bioavailability and tissue residues were determined in broiler chickens."( Pharmacokinetic profile and tissue distribution of monensin in broiler chickens.
abo el-Sooud, K; Atef, M; Ramadan, A, 1993
)
0.84
" The potential of ODNs for modulating liver-specific genes might be increased by preventing untimely elimination and by improving the local bioavailability of ODNs in the target tissue."( Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo.
Biessen, EA; Bijsterbosch, MK; Fluiter, K; Kuiper, J; Rump, ET; van Berkel, TJ; Vietsch, H, 1999
)
0.3
"The oral bioavailability of poorly water-soluble drugs (PWSD) is often significantly enhanced by coadministration with lipids in food or lipid-based oral formulations."( Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation.
Charman, WN; Porter, CJ; Quach, T; Trevaskis, NL; Tso, P; Yeap, YY, 2013
)
0.39
" Monensin inhibited the degradation of atrazine, changed the metabolite patterns in soil, and increased the bioavailability of atrazine in earthworms."( Co-exposure of Monensin Increased the Risks of Atrazine to Earthworms.
Jiang, W; Liu, D; Liu, X; Wang, F; Wang, P; Yu, X; Zhai, W, 2022
)
1.98
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Monensin did not accumulate in the tissues of orally dosed animals. The biphasic dose-response curve for CCK-stimulated enzyme secretion from monensin-treated acini suggests that pancreatic acini also possess a third, previously unrecognized class of very low affinity CCK receptors.

ExcerptRelevanceReference
" A dose-response relationship was established, and it was found that the lowest doses of monensin (5-25 micrograms/kg) produced a dose-dependent increase (3-5x) in CBF with a concomitant decrease in total peripheral resistance (TPR)."( Characterization of the coronary vasodilator and hemodynamic actions of monensin, a carboxylic ionophore.
Hester, RK; Pressman, BC; Saini, RK; Somani, P,
)
0.59
" E brunetti was not so markedly affected, although oocyst sporulation was reduced by the higher dosage levels."( The anticoccidial effects of amprolium, dinitolmide and monensin against Eimeria maxima, E, brunetti and E. acervulina with particular reference to oocyst sporulation.
Joyner, LP; Norton, CC, 1977
)
0.5
" Conversely, the relationship of plasma pigmentation and total lesion scores to monensin feed levels indicated that increasing the dosage of monensin from 100 to 121 ppm improved the performance of the broilers on the basis of these 2 infection indicators."( Efficacy of different feeding levels of monensin in the control of coccidiosis in broilers.
Rahn, AP; Reid, WM; Ruff, MD, 1976
)
0.75
" Average daily gain was increased in steers as daily monensin dosage increased from 120 to 180 mg (P less than ."( Nitrogen utilization by ruminants during restricted intake of high-concentrate diets.
Pritchard, RH; Sip, ML, 1991
)
0.53
" Moreover, the biphasic dose-response curve for CCK-stimulated enzyme secretion from monensin-treated acini suggests that pancreatic acini also possess a third, previously unrecognized class of very low affinity CCK receptors."( Down-regulation and recycling of high affinity cholecystokinin receptors on pancreatic acinar cells.
Gardner, JD; Jensen, RT; Menozzi, D; Vinayek, R, 1991
)
0.51
" Concurrent administration of monensin sodium at a constant safe dosage enhanced the toxicity of selenium as demonstrated by increased severity of the signs of intoxication, fatalities, tissue selenium concentrations and intensified gross, histopathological and histochemical changes."( Effects of concurrent oral administration of monensin on the toxicity of increasing doses of selenium in lambs.
Barlow, RM; Humphreys, DJ; Robins, M; Smyth, JB; Stodulski, JB; Wang, JH, 1990
)
0.83
" Dose-response studies showed, however, that the State 2 pathway was more sensitive to leupeptin or monensin than the State 1 pathway."( Differential effects of leupeptin, monensin and colchicine on ligand degradation mediated by the two asialoglycoprotein receptor pathways in isolated rat hepatocytes.
Clarke, BL; Weigel, PH, 1989
)
0.77
"When they were turned out to grass in May 1987 for their first season, 10 calves were dosed with a 5 x 750 mg oxfendazole pulse release bolus (OPRB) and a monensin sodium rumen delivery device (RDD); eight calves received one OPRB; 10 calves received one RDD and eight calves received neither bolus."( Concurrent use of the oxfendazole pulse release bolus and the monensin rumen delivery device in young grazing cattle.
McEvoy, CM; Rowlands, DT; Woollon, RM, 1989
)
0.72
" Chromic oxide was dosed to determine fecal output, and ruminal samples were collected on d 6 of each period."( Effects of a monensin ruminal delivery device on daily gain, forage intake and ruminal fermentation of steers grazing irrigated winter wheat pasture.
Branine, ME; Davenport, RW; Galyean, ML; Hubbert, ME, 1989
)
0.65
" Ten days after the start of this regime, groups of the ewes were dosed orally with nil, 2000 or 12,000 sporulated Toxoplasma gondii oocysts."( Further studies in the use of monensin in the control of experimental ovine toxoplasmosis.
Blewett, DA; Buxton, D; Finlayson, J; McColgan, C; Trees, AJ, 1988
)
0.56
" Prominent acute clinical signs of monensin toxicosis (hypermetria, hind limb ataxia, paresis, knuckling of hind limbs, and recumbency) developed by 2 to 6 hours after dosing in pigs given 15 or 25 mg of monensin/kg with tiamulin exposure, but not in pigs given the 15 or 25 mg of monensin/kg without tiamulin exposure."( Monensin toxicosis in swine: potentiation by tiamulin administration and ameliorative effect of treatment with selenium and/or vitamin E.
Cook, JR; Runnels, LJ; Scheidt, AB; Van Vleet, JF, 1987
)
1.99
" A total dosage per quail of 10(6) sporulated oocysts was chosen because this dosage gave a good (77%) depression of weight gain from Day 18 to Day 24."( Prevention of coccidiosis in bobwhites by medication.
Chute, MB; Ruff, MD; Wilkins, GC, 1987
)
0.27
" With increasing dosage of monensin, secreted and intracellular ASB activity increased for both OA and normal cells."( Monensin stimulation of arylsulfatase B activity in human chondrocytes.
Colofiore, JR; Schwartz, ER, 1986
)
2.01
" In both experiments coccidial lesions and oocyst output were controlled more effectively as monensin dosage was increased."( Monensin efficacy in rations containing suboptimal energy or protein.
Bafundo, KW, 1986
)
1.93
" The cattle were given (orally) a single dosage of lasalocid (1, 10, 50, or 100 mg/kg of body weight) or monensin (25 mg/kg of body weight) or rice hulls."( Pathologic changes associated with experimental lasalocid and monensin toxicosis in cattle.
Galitzer, SJ; Kidd, JR; Kruckenberg, SM, 1986
)
0.73
" Rumen and blood samples were obtained before and at 6, 12, and 24 hours after each carbohydrate-antibiotic dosing to monitor acid-base status."( Effect of ionophore antibiotics on experimentally induced lactic acidosis in cattle.
Avery, TB; Galitzer, SJ; Harmon, DL; Nagaraja, TG, 1985
)
0.27
" Monensin did not accumulate in the tissues of orally dosed animals."( Biochemical studies on the fate of monensin in animals and in the environment.
Donoho, AL, 1984
)
1.45
" The optimal dosage level was shown to be 5 ppm in the diet."( CL 259,971: a potent new polyether anticoccidial. 2. Floor-pen trials.
Kantor, S; Kennett, RL; Schenkel, RH, 1984
)
0.27
" In each of 4 pens (pens 2 to 5), 1 calf was inoculated with sporulated oocysts of Eimeria bovis (and was not medicated); 1 calf was inoculated and given feed with added monensin at the dosage level of 10 g/906 kg of feed; and 2 calves were inoculated and given medicated feed with added monensin at the dosage level of 20 g/906 kg or 30 g/906 kg."( Control of bovine coccidiosis with monensin: in nonresistant newborn calves.
Fitzgerald, PR; Mansfield, ME, 1984
)
0.74
"The effects were studied of sodium monensinate dosed 125 mg on the metabolic profile of rumen fluid."( [The effect of Rumensin on the metabolic profile of rumen fluid in feedlot cattle].
Dvorák, J; Dvorák, R; Hradilová, M; Ondrová, J; Vrba, Z, 1980
)
0.54
"The effect was studied of sodium monensinate dosed 125 mg pro die and given to feeder cattle on the health condition and some clinico-biochemical parameters in view of the energy metabolism."( [The effect of Rumensin on the health status and energy metabolism of feedlot cattle].
Bouda, J; Dvorák, J; Dvorák, R; Vrba, Z, 1980
)
0.54
"One hundred ninety-two male broiler chicks were dosed with monensin at concentrations of 0, 121, or 242 mg/kg feed throughout the normal growing period (50 days)."( Subchronic toxicity of monensin in broiler chickens.
Bradley, BD; Furrow, RD; Wagner, DD, 1983
)
0.82
" Inhibition was maintained for long periods by single daily dosing directly into the rumen or by dietary administration."( Properties of a novel series of inhibitors of rumen methanogenesis; in vitro and in vivo experiments including growth trials on 2,4-bis (trichloromethyl)-benzo [1, 3]dioxin-6-carboxylic acid.
Boyle, FT; Davies, A; Nwaonu, HN; Stanier, G, 1982
)
0.26
" Four rumen-fistulated cattle were used for each dosage level and the design was a 4 x 4 Latin square with each animal receiving lasalocid, monensin, thiopeptin or no antibiotic."( Effect of lasalocid, monensin or thiopeptin on lactic acidosis in cattle.
Avery, TB; Bartley, EE; Dayton, AD; Nagaraja, TG; Roof, SK, 1982
)
0.78
" Total VFA concentration, protozoa numbers, and NDF digestibility were not depressed significantly at this dosage but were reduced at 100 mg/d with little further increase in the molar percentage of propionate."( Effect of aibellin, a peptide antibiotic, on propionate production in the rumen of goats.
Hino, T; Kanda, M; Kumazawa, S; Miwa, T; Saitoh, H, 1994
)
0.29
"75% BW) or steers were dosed intraruminally with a 100% concentrate diet."( Efficacy of laidlomycin propionate to reduce ruminal acidosis in cattle.
Bauer, ML; Britton, RA; Herold, DW; Klopfenstein, TJ; Stock, RA; Yates, DA, 1995
)
0.29
" However, inhibition reached the maximal level only at 50 mM sodium, and typical sigmoidal dose-response curves were obtained only in the presence of 118 mM sodium."( Regulation of mu-opioid receptor in neural cells by extracellular sodium.
Medzihradsky, F; Yabaluri, N, 1997
)
0.3
"Monensin, a polyether ionophore antibiotic used worldwide for its anticoccidial and growth-promoting properties, is reported to act as anin vivo inducer or inhibitor of drug-metabolizing enzyme systems in various species according to dosage regimens and duration of exposure."( 'In vitro' interactions of monensin with hepatic xenobiotic metabolizing enzymes.
Carletti, M; Ceppa, L; Dacasto, M; Montesissa, C; Nebbia, C, 1997
)
2.04
" On d 21, rumens were dosed 2 h after the morning feeding with 350 g of solubilized casein to evaluate in vivo ruminal protease and deaminase activities."( Effects of virginiamycin and monensin plus tylosin on ruminal protein metabolism in steers fed corn-based finishing diets with or without wet corn gluten feed.
Bindel, DJ; del Barrio, A; Hollis, LC; Ives, SE; Nagaraja, TG; Titgemeyer, EC, 2002
)
0.61
" Theoretical maximum concentration estimated from the actual dosing rate and the theoretical excretion rate assuming no attenuation was one order of magnitude greater than observed concentrations, suggesting significant attenuation in the manure collection and storage system."( Environmental occurrence and shallow ground water detection of the antibiotic monensin from dairy farms.
Bergamaschi, BA; Harter, TH; Watanabe, N,
)
0.36
"45% urea plus monensin sodium (Rumensin, at the intermediate dosage from the label, 16 g/909 kg of dry matter; MUR)."( Interaction of molasses and monensin in alfalfa hay- or corn silage-based diets on rumen fermentation, total tract digestibility, and milk production by Holstein cows.
Firkins, JL; Oelker, ER; Reveneau, C, 2009
)
1.01
" The absorption, elimination and partition parameters will be incorporated into a physiologically based pharmacokinetic model and the depletion study will be used to test the ability of this model to describe monensin residues in edible tissues under different dosage regimens."( Bioavailability, distribution and depletion of monensin in chickens.
Burel, C; Henri, J; Laurentie, M; Sanders, P, 2009
)
0.8
" Monensin, salinomycin and maduramycin at the dosage of 120, 60, and 5 mg/kg were administered in feed for 14 days."( Effects of ionophores on liver CYP1A and 3A in male broilers.
Jiang, SX; Mo, F; Yu, ZG; Zhang, JR; Zhang, LL; Zhao, J, 2010
)
1.27
" Dose-response studies suggest a rather small effective concentration range and time-effect data show a primary and transient up-regulation of GR-α mRNA levels and a down-regulation of GR-β mRNA levels after 16 h of treatment."( Hypericum perforatum differentially affects corticosteroid receptor-mRNA expression in human monocytic U-937 cells.
Enning, F; Krieg, JC; Murck, H; Vedder, H, 2011
)
0.37
" This validated PBPK model may also be useful for interspecies extrapolations or withdrawal period calculations for modified dosage regimens."( A physiologically based pharmacokinetic model for chickens exposed to feed supplemented with monensin during their lifetime.
Carrez, R; Henri, J; Laurentie, M; Méda, B; Sanders, P, 2017
)
0.67
" Flocculated rumen fluid was incubated in batch culture dosed with N-free feed only (control), MON, CIN, or a combination of MON+CIN."( Using video microscopy to improve quantitative estimates of protozoal motility and cell volume.
Firkins, JL; Wagner, BK; Wenner, BA, 2018
)
0.48
" Monensin did not reduce methane production at concentrations expected in dairy manure at recommended dosage rates."( The fate and effect of monensin during anaerobic digestion of dairy manure under mesophilic conditions.
Arikan, OA; Lansing, S; Mulbry, W; Rice, C, 2018
)
1.7
" At higher concentrations of monensin, which we dosed directly to control manure (from dairy cows without monensin), we observed major changes in the microbiome composition and function of two anaerobic digesters."( Redundancy in Anaerobic Digestion Microbiomes during Disturbances by the Antibiotic Monensin.
Angenent, LT; Daly, SE; Spirito, CM; Werner, JJ, 2018
)
1
" This study was designed to gather published data of virginiamycin (VM) used in feedlot conditions of the United States and analyze its effectiveness and optimum dosage in reducing the liver abscess incidence (LAI)."( An assessment of the effectiveness of virginiamycin on liver abscess incidence and growth performance in feedlot cattle: a comprehensive statistical analysis.
Gorocica-Buenfil, MA; Tedeschi, LO, 2018
)
0.48
"The aim of this study was to conduct a comprehensive review with meta-analysis to determine the effects of the dose-response relationship between monensin supplementation and dairy cow performance and milk composition."( Effects of monensin supplementation on lactation performance of dairy cows: a systematic review and dose-response meta‑analysis.
Ghaffari, MH; Norouzian, MA; Piray, AH; Rezaei Ahvanooei, MR; Vahmani, P, 2023
)
1.5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
coccidiostatAn agent useful in the treatment or prevention of coccidiosis in man or animals.
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
ionophoreA compound which can carry specific ions through membranes of cells or organelles.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
polyether antibiotic
monocarboxylic acidAn oxoacid containing a single carboxy group.
cyclic hemiketalA hemiacetal having the structure R2C(OH)OR (R =/= H), derived from a ketone by formal addition of an alcohol to the carbonyl group. The term 'cyclic hemiketals', once abandoned by IUPAC, has been reinstated as a subclass of hemiacetals.
spiroketalA cyclic ketal in which the ketal carbon is the only common atom of two rings.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency0.22140.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency1.25650.000221.22318,912.5098AID743035; AID743042; AID743054; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.25530.000214.376460.0339AID720691; AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency4.78950.000229.305416,493.5996AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
67.9K proteinVaccinia virusPotency31.62280.00018.4406100.0000AID720580
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency1.12200.10009.191631.6228AID1346983
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency14.12540.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.30260.000323.4451159.6830AID743065; AID743067
Cellular tumor antigen p53Homo sapiens (human)Potency17.21770.002319.595674.0614AID651631
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency0.47310.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency0.47310.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (141)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (152)

Assay IDTitleYearJournalArticle
AID716382Toxicity in chronic oral dosed mouse after 2 years2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Polyether ionophores-promising bioactive molecules for cancer therapy.
AID509719Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 291/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID329009Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 18 hrs by serial agar dilution method2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID509735Antimicrobial activity against methicillin-resistant Staphylococcus aureus 334/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID670791Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus 482/11 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID624622Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID716385Toxicity in subchronic oral dosed dog after 1 year2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Polyether ionophores-promising bioactive molecules for cancer therapy.
AID51092Anticoccidial activity in chicken against Eimeria acervulina.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID329028Antibacterial activity against Bordetella bronchiseptica ATCC 4617 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID670784Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus 399/10 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID670801Antibacterial activity against hospital-acquired methicillin-sensitive Staphylococcus aureus 449/11 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID509734Antimicrobial activity against methicillin-resistant Staphylococcus aureus 333/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID554737Inhibition of Candida krusei ABC1 expressed in Saccharomyces cerevisiae isolate ADdelta at 12 nM2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID670793Antibacterial activity against hospital-acquired methicillin-sensitive Staphylococcus aureus 441/11 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID329020Antibacterial activity against Escherichia coli ATCC 10538 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID670785Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus 400/10 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID1248019Antiproliferative activity against human MV4-11 cells2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Anti-proliferative activity of Monensin and its tertiary amide derivatives.
AID670796Antibacterial activity against hospital-acquired methicillin-sensitive Staphylococcus aureus 444/11 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID329003Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by serial agar dilution method2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID329033Antifungal activity against Candida parapsilosis ATCC 22019 at 400 ug/disc after 24 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID509740Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 322/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID509746Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 339/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID324583Increase in long-lived protein degradation in human H4 cells after 2 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID519607Cytotoxicity against Hepatocyte cells assessed as cell viability by MTT assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID509722Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 311/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID519608Selectivity index, ratio of TC50 for hepatocytes to IC50 for Plasmodium yoelii 2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID324585Increase in long-lived protein degradation in human H4 cells after 24 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID329011Antibacterial activity against Bacillus subtilis ATCC 6633 after 18 hrs by serial agar dilution method2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID509718Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 290/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID51234The compound was tested for anti-coccidial activity in chicken against Eimeria brunetti (FS-103) measured at dose 121 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID329014Antibacterial activity against Enterococcus hirae ATCC 10541 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID624623Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID509721Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 293/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID509728Antimicrobial activity against methicillin-resistant Staphylococcus aureus 308/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID670794Antibacterial activity against hospital-acquired methicillin-sensitive Staphylococcus aureus 442/11 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID324477Increase in light chain 3-GFP+ autophagosome vesicle area per cell in human H4 cells at 3.6 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID51404The compound was tested for anti-coccidial activity in chicken against Eimeria praecox (DP-785) measured at dose 121 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID509744Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 328/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID329012Antibacterial activity against Bacillus cereus ATCC 11778 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID329007Antibacterial activity against Staphylococcus aureus ATCC 29213 after 18 hrs by serial agar dilution method2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID670795Antibacterial activity against hospital-acquired methicillin-sensitive Staphylococcus aureus 443/11 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID324580Decrease in FYVE-RFP+ vesicle intensity per cell in human H4 cells after 4 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID509743Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 327/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID509737Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 319/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID519606Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID670798Antibacterial activity against hospital-acquired methicillin-sensitive Staphylococcus aureus 446/11 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID324584Increase in long-lived protein degradation in human H4 cells after 4 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID324579Decrease in FYVE-RFP+ vesicle intensity per cell in human H4 cells after 2 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID324373Induction of light chain 3-GFP level in human H4 cells at 3.6 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID670789Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus 452/11 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID670800Antibacterial activity against hospital-acquired methicillin-sensitive Staphylococcus aureus 448/11 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID1248017Antiproliferative activity against human LoVo cells2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Anti-proliferative activity of Monensin and its tertiary amide derivatives.
AID716386Inhibition of MDR in multidrug-resistant human KB cells assessed as increase of doxorubicin accumulation after 1 hr relative to control2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Polyether ionophores-promising bioactive molecules for cancer therapy.
AID509738Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 320/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID681130TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1248018Antiproliferative activity against human LoVo/DX cells2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Anti-proliferative activity of Monensin and its tertiary amide derivatives.
AID624626Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID681121TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1248023Resistance index, ratio of IC50 for human LoVo/DX cells to IC50 for human LoVo cells2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Anti-proliferative activity of Monensin and its tertiary amide derivatives.
AID670790Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus 481/11 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID51412Anticoccidial activity in chicken against E. tenella1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID329002Antibacterial activity against Staphylococcus aureus ATCC 25923 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID1248020Cytotoxicity against mouse BALB/3T3 cells2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Anti-proliferative activity of Monensin and its tertiary amide derivatives.
AID509720Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 292/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID509717Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 289/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID509724Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 316/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID324582Increase in long-lived protein degradation in human H4 cells after 1 hr relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID670782Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus 393/10 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID624629Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID670783Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus 394/10 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID329004Antibacterial activity against Staphylococcus aureus ATCC 6538 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID670788Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus 451/11 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID716387Potentiation of SWA11-ricin-A chain-induced cytotoxicity in human clonogenic tumor cells at 1 x 10'-7 M relative to control2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Polyether ionophores-promising bioactive molecules for cancer therapy.
AID509729Antimicrobial activity against methicillin-resistant Staphylococcus aureus 309/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID329031Antifungal activity against Candida albicans ATCC 90028 at 400 ug/disc after 24 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID509731Antimicrobial activity against methicillin-resistant Staphylococcus aureus 330/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID329013Antibacterial activity against Bacillus cereus ATCC 11778 after 18 hrs by serial agar dilution method2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID670792Antibacterial activity against hospital-acquired methicillin-sensitive Staphylococcus aureus 440/11 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID51415The compound was tested for anti-coccidial activity in chicken against Eimeria tenella (DP-761) measured at dose 121 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID329025Antibacterial activity against Pseudomonas aeruginosa ATCC 15442 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID329001Antibacterial activity against Staphylococcus aureus NCTC 4163 after 18 hrs by serial agar dilution method2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID51243The compound was tested for anti-coccidial activity in chicken against Eimeria hagani (DP-786) measured at dose 121 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID329027Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID1248022Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LoVo/Dx cells2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Anti-proliferative activity of Monensin and its tertiary amide derivatives.
AID329016Antibacterial activity against Micrococcus luteus ATCC 9341 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID509745Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 338/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID509739Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 321/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID329006Antibacterial activity against Staphylococcus aureus ATCC 29213 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID509741Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 324/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID329026Antibacterial activity against Pseudomonas aeruginosa NCTC 6749 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID716381Toxicity in subchronic oral dosed dog after 3 months2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Polyether ionophores-promising bioactive molecules for cancer therapy.
AID716389Antiproliferative activity against human SNU-C1 cells assessed as growth inhibition at 0.5 uM2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Polyether ionophores-promising bioactive molecules for cancer therapy.
AID51095The compound was tested for anti-coccidial activity in chicken against Eimeria acervulina (DP-761) measured at dose 121 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID329029Antifungal activity against Candida albicans ATCC 10231 at 400 ug/disc after 24 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID509730Antimicrobial activity against methicillin-resistant Staphylococcus aureus 329/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID509726Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 318/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID51257The compound was tested for anti-coccidial activity in chicken against Eimeria mitis (LS-84) measured at dose 121 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID329005Antibacterial activity against Staphylococcus aureus ATCC 6538 after 18 hrs by serial agar dilution method2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID329018Antibacterial activity against Micrococcus luteus ATCC 10240 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID329010Antibacterial activity against Bacillus subtilis ATCC 6633 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID716383Toxicity in chronic oral dosed rat after 2 years2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Polyether ionophores-promising bioactive molecules for cancer therapy.
AID1248021Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LoVo cells2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Anti-proliferative activity of Monensin and its tertiary amide derivatives.
AID716388Antiproliferative activity against human NCI-H929 cells assessed as growth inhibition at 0.5 uM2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Polyether ionophores-promising bioactive molecules for cancer therapy.
AID716384Toxicity in subchronic oral dosed rat after 3 months2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Polyether ionophores-promising bioactive molecules for cancer therapy.
AID509732Antimicrobial activity against methicillin-resistant Staphylococcus aureus 331/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID324425Increase in light chain 3-GFP+ autophagosome vesicle number per cell in human H4 cells at 3.6 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID509742Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 326/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID519609Antimicrobial activity against Plasmodium falciparum NF54 schizonts in mammalian hepatocytes after 96 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID324529Increase in light chain 3-GFP+ autophagosome vesicle intensity per cell in human H4 cells at 3.6 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID329017Antibacterial activity against Micrococcus luteus ATCC 9341 after 18 hrs by serial agar dilution method2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID324581Decrease in FYVE-RFP+ vesicle intensity per cell in human H4 cells after 8 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID670799Antibacterial activity against hospital-acquired methicillin-sensitive Staphylococcus aureus 447/11 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID329023Antibacterial activity against Proteus vulgaris NCTC 4635 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID509725Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 317/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID509736Antimicrobial activity against methicillin-resistant Staphylococcus aureus 335/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID329000Antibacterial activity against Staphylococcus aureus NCTC 4163 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID51248The compound was tested for anti-coccidial activity in chicken against Eimeria maxima (DP-776) measured at dose 121 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID728624Inhibition of Clostridium botulinum recombinant neurotoxin A light chain using SNAPtide as substrate at 10 uM after 1 hr by FRET assay relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A.
AID670797Antibacterial activity against hospital-acquired methicillin-sensitive Staphylococcus aureus 445/11 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID509727Antimicrobial activity against methicillin-resistant Staphylococcus aureus 307/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID329019Antibacterial activity against Micrococcus luteus ATCC 10240 after 18 hrs by serial agar dilution method2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID509723Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 315/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID670787Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus 450/11 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID1248024Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human MV4-11 cells2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Anti-proliferative activity of Monensin and its tertiary amide derivatives.
AID509733Antimicrobial activity against methicillin-resistant Staphylococcus aureus 332/08 after 18 hrs by disc-diffusion method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Structural characterization and antibacterial activity against clinical isolates of Staphylococcus of N-phenylamide of monensin A and its 1:1 complexes with monovalent cations.
AID329021Antibacterial activity against Escherichia coli ATCC 25922 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID329022Antibacterial activity against Escherichia coli NCTC 8196 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID624628Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID329008Antibacterial activity against Staphylococcus epidermidis ATCC 12228 at 400 ug/disc after 18 hrs by disc diffusion assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID670786Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus 401/10 after 18 hrs by twofold serial agar dilution technique2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin.
AID329015Antibacterial activity against Enterococcus hirae ATCC 10541 after 18 hrs by serial agar dilution method2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis and antimicrobial properties of monensin A esters.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1717752cytotoxicity against golden hamster BHK-21 cells incubated for 72 hrs by MTT assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1195543Antimicrobial activity against Bacillus anthracis 34F2 after 18 hrs by twofold serial broth dilution method2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Tertiary amides of Salinomycin: A new group of antibacterial agents against Bacillus anthracis and methicillin-resistant Staphylococcus epidermidis.
AID1717753Selectivity index, ratio of CC50 for golden hamster BHK-21 cells to EC50 for wild type HCoV-OC43 infected in BHK-21 cells2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID685501HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells2012Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID685500HARVARD: Cytotoxicity in HepG2 cell line2012Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1717751Antiviral activity against wild type HCoV-OC43 infected in BHK-21 cells incubated for 72 hrs by RT-PCR method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1717771Selectivity ratio of CC50 for Rhesus macaque LLC-MK2 cells to EC50 for HCoV-NL63 infected in Rhesus macaque LLC-MK2 cells2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1717770Cytotoxicity against Rhesus macaque LLC-MK2 cells incubated for 72 hrs by MTT assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1717769Antiviral activity against HCoV-NL63 infected in Rhesus macaque LLC-MK2 cells incubated for 72 hrs by RT-PCR method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,220)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901263 (39.22)18.7374
1990's980 (30.43)18.2507
2000's518 (16.09)29.6817
2010's344 (10.68)24.3611
2020's115 (3.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 55.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index55.19 (24.57)
Research Supply Index8.15 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index96.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (55.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials115 (3.45%)5.53%
Trials0 (0.00%)5.53%
Reviews69 (2.07%)6.00%
Reviews1 (11.11%)6.00%
Case Studies22 (0.66%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other3,130 (93.82%)84.16%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Compression in Anklefracture Treatment, The CAT-study [NCT02481076]156 participants (Actual)Interventional2013-11-30Active, not recruiting
A Randomized, Controlled, Clinical Study to Assess a New Adjustable Compression Device in Patients With Venous Leg Ulcers [NCT02561013]0 participants (Actual)Interventional2015-09-30Withdrawn(stopped due to Business reasons)
Preliminary Study to Assess the Effectiveness of 3M Oedema Reduction System in the Treatment of Lymphoedema Treatment Compared to Comprilan Short-stretch Bandage Compression Therapy [NCT01096589]82 participants (Actual)Interventional2010-03-31Completed
Day One Post Operative Range of Motion Following Skin Graft to Hand With Intraoperative Coban Dressing [NCT01027520]6 participants (Actual)Interventional2010-01-31Terminated(stopped due to Insufficient enrollment numbers)
Randomized Controlled Clinical Study to Assess the Clinical Efficacy of the 3M™ Coban™ 2 Layer Compression System Compared to a Short-stretch Compression Bandage in the Treatment of Venous Leg Ulcers [NCT00558662]234 participants (Actual)Interventional2007-11-30Completed
Randomised Controlled Trial to Compare the Influence of Sub-bandage Pressure on Percentage Volume Reduction of Leg Lymphoedema [NCT01828606]60 participants (Actual)Interventional2013-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01096589 (2) [back to overview]Assessment of Safety by Incidence of Adverse Events.
NCT01096589 (2) [back to overview]Percent Volume Change of Affected Limb at End of Treatment Compared to Baseline.

Assessment of Safety by Incidence of Adverse Events.

(NCT01096589)
Timeframe: 3 weeks

InterventionNo. of treatment-emergent adverse events (Number)
Arm 1 - 3M Coban 213
Arm 2 - 3M Coban 211
Arm 3 - 3M Coban 214
Arm 4 - Comprilan10

[back to top]

Percent Volume Change of Affected Limb at End of Treatment Compared to Baseline.

(NCT01096589)
Timeframe: baseline and after 3 weeks of treatment

Intervention% volume change measured in mL. (Mean)
Arm 1 - 3M Oedema Reduction System-14.56
Arm 2 - 3M Oedema Reduction System-7.09
Arm 3 - 3M Oedema Reduction System-10.24
Arm 4 - Commercial Compression System 5 Apps/wk-9.84

[back to top]